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ABSTRACT 
 
UTILIZATION OF AQUEOUS RAFT SYNTHESIZED COPOLYMERS TO 
 
 IMPROVE ANTICANCER DRUG EFFICACY 
 
by Andrew Christopher Holley 
 
December 2014 
 
The advent of controlled radical polymerization (CRP) techniques, along with 
advancements in facile conjugation chemistry, now allow synthetic tailoring of precise, 
polymeric architectures necessary for drug/gene delivery.  Reversible addition-
fragmentation chain transfer (RAFT) polymerization and its aqueous counterpart 
(aRAFT) afford quantitative control over key synthetic parameters including block 
length, microstructure, and placement of structo-pendent and structo-terminal 
functionality for conjugation of active agents and targeting moieties.  The relevance of 
water-soluble and amphiphilic (co)polymers synthesized by RAFT for in vitro delivery of 
therapeutics in biological fluids is an especially attractive feature.  In many cases, 
polymerization, binding, conjugation, and stimulus-induced release can be accomplished 
directly in aqueous media. However, specific problems, barriers, and challenges 
regarding rational design of polymeric delivery systems for therapeutic siRNA still exist. 
 This dissertation focuses on RAFT synthesized (co)polymers as vectors and 
functional constructs to overcome delivery challenges.  In section I, a modular copolymer 
consisting of HPMA and glutamic acid was synthesized to overcome hurdles of 
endosomal escape. Glutamic acid undergoes a coil-to-helix transition at endosomal pH-
values, and these helices were stabilized with HPMA. As a proof-of-concept, the pH-
responsive constructs demonstrated membrane disruption via red blood cell hemolysis 
and dye release from fluorescein-loaded POPC vesicles. In section II, hydrophilic-block-
iii 
 
cationic copolymers were complexed with siRNA to ascertain the structure-property 
relationships governing siRNA release from block ionomer complexes (BICs). It was 
determined that the stability of the complexes, which increases with increasing cationic 
block length, delayed the time required to achieve gene suppression. These results 
indicated that decomplexation was facilitated via an ion exchange/substitution 
mechanism. In section III, AS1411, an anticancer biologic, was delivered utilizing 
hydrophilic-block-cationic copolymers. The prepared BICs were found to be 
monodisperse (PDIs < 0.1) and charge neutral (i.e., N:P = 1). The anti-proliferative 
ability of AS1411 was then assessed utilizing hydrophilic-block-cationic copolymers as 
delivery vehicles. After 72 h, AS1411 demonstrated successful cellular inhibition; 
however, negligible anti-proliferative activity was witnessed when AS1411 was delivered 
utilizing hydrophilic-block-cationic copolymers. This reduction in drug activity was 
attributed to reduction of available drug caused by increased BIC stability as was 
determined in Section II. 
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CHAPTER I 
 
INTRODUCTION 
 
 The targeted delivery of nucleic acid-based therapeutics has recently become one 
of the most active areas of research in the rapidly developing field of nanomedicine.  
Unprecedented advances in synthetic polymer chemistry over the last decade now allow 
for precise control of macromolecular structure and thus rational design of biologically-
relevant carriers with functional components engineered to aid in stabilization, trafficking 
and stimulus-induced release of “packaged” therapeutic agents.  This chapter will focus 
exclusively on synthetic (co)polymers and their conjugates  prepared via controlled 
radical polymerization (CRP) that have potential for therapeutic delivery of small 
interfering  RNA (siRNA). Criteria for efficient delivery and efficient gene “knockdown” 
through the RNA interference (RNAi) are presented based on current understanding of 
cellular delivery pathways. Emphasis is placed on synthetic carrier structures and features 
of controllable segments which lend themselves to polyplex formation, siRNA packaging, 
targeting, uptake, endosomal escape, and delivery to messenger RNA (mRNA) targets.   
 Although research with siRNA/CRP polymers is in its infancy relative to more 
mature areas of DNA therapy, rapid growth is forecasted due to fewer intra-cellular 
barriers to delivery and to the structural control afforded by new synthetic techniques, 
often accomplished directly in aqueous media.  It is interesting to note from a historical 
perspective that discoveries of the RNA interference (RNAi) pathway
1
 and reversible 
addition-fragmentation chain transfer (RAFT) polymerization
2
 were both reported in 
1998.   
 
 
2 
 
 
Rational Design of Polymer-Based Delivery Vehicles 
 The concept of tailoring synthetic polymer vehicles (vectors) for site-selected 
delivery and release of therapeutic agents was pioneered by Ringsdorf over 35 years ago.
6
 
He and his colleagues suggested a simple “depot” model (Figure 1) in which the 
therapeutic agent could be attached in a facile manner via a hydrolytically- or 
enzymatically-degradable spacer to a water-soluble, non-immunogenic (co)polymer 
backbone having requisite components  for complex  protection, solubility and circulation 
under physiological conditions.  Therapeutic cargo could be trafficked either passively or 
actively (the latter by including targeting moieties) to specific “depot” sites for stimulus-
induced release as directed by endogenous cell components.  The model was later 
extended for attachment of a diagnostic component to track location of the carrier, thus 
setting the stage for dual purpose theranostic (therapeutic/diagnostic) vehicles. The 
concepts of this seminal model remain at the forefront of rational design strategies for 
polymeric vehicles utilized for pharmaceutical delivery, including siRNA therapeutics.  
However, only recently have facile polymerization and orthogonal chemistries been 
developed that yield precise architectures, segment lengths, selected sizes, functionality, 
and narrow molecular weight distributions required.  For example, the CRP syntheses of 
well-defined (co)polymers with pH-responsive, tertiary and secondary amine segments 
necessary for reversible polyplex formation with polynucleotides have recently been 
reported.
7
  More specifically, rationally-designed siRNA polyplexes with targeting 
moieties have shown therapeutic potential in vitro as demonstrated by cell-specific 
delivery and gene silencing via the RNAi pathway.  It should be noted that despite 
fundamental distinctions of nucleotide structure and trafficking,
8
 many of the recent 
approaches to siRNA delivery have precedence in DNA delivery utilizing a variety of 
3 
 
 
polymer types including classical, or controlled chain growth polymers, dendrimers, 
polymers from ring-opening polymerization, and those prepared from synthetic-
bioconjugate techniques. Nano- and micro-structured particles, micelles, polymersomes, 
microemulsions, hydrogels, transition metal complexes, carbon nanotubes, and inorganic 
complexes have been reported.  The reader is directed to a number of comprehensive 
reviews of these DNA delivery vectors.
9–20
  
 
 
Figure 1.  Components of the Ringsdorf “depot” model. 
 
 
RNA Interference (RNAi) 
 RNA interference (RNAi) is a gene silencing effect induced by RNA duplexes 
that ultimately results in messenger RNA (mRNA) cleavage, thus inhibiting expression of 
target proteins.  Importantly, RNAi potentially offers a pathway for therapeutic treatment 
of a variety of diseases including genetic, degenerative, and viral diseases as well as 
cancer.
21
  In a recent Chemical Society Review,
22
 Gaynor et al. present the mechanism of 
RNAi as currently understood.  A simplified seven step pathway (Figure 2) is detailed 
that starts with the formation of siRNA duplexes generally 21–23 nucleotides in length 
and having a two-nucleotide overhang at the 3’ end.  The duplexes, which can be 
prepared synthetically or by endogenous processing of longer hairpin or double-stranded 
RNA (dsRNA), have precise sequences such that the antisense or “guide” strand is 
4 
 
 
complimentary to the target messenger RNA (mRNA) transcribed from the gene to be 
“silenced.”  The siRNA duplex associates with cytoplasm proteins and is trafficked to the 
RNA-induced silencing complex (RISC) for removal of the sense or “passenger” strand, 
thus activating the complex for target mRNA recognition and complementary binding.  
RISC contains a protein with endoribonuclease activity that cleaves the mRNA backbone 
specifically between nucleotides 10 and 11 relative to the 5’ end of the guide strand.  
Ideally, after dissociation from the cleaved mRNA, recycled RISC can then target other 
mRNA strands.  For further discussion of kinetics, biodistribution, stabilization, cellular 
uptake, chemical modification, possible interferon response, and off-target effects 
operative in RNAi, the reader is referred to several recent reviews.
21–29
 
 
 
 
 
Figure 2.  The RNA interference (RNAi) pathway.
22
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Barriers to siRNA and General Approaches to Therapeutic Delivery 
 
 RNAi therapy has been highly touted due to its simplicity (relative to other forms 
of oligonucleotide intervention) and applicability to a large number of diseases.  
Advantages are that interference occurs at the translational rather than the transcriptional 
level, relatively small doses of siRNA are required, and lower toxicity is generally 
observed.   However, efficient delivery necessitates overcoming significant barriers 
(Figure 3) that stem from the physicochemical properties of siRNA and systemic 
interactions during trafficking to cytoplasm targets.
23–29
 
 
 
 
 
Figure 3.  Cellular barriers to oligonucleotide delivery.
21
 
 
 
 Cellular delivery of siRNA and other polynucleotide therapeutics has been 
accomplished utilizing a number of viral and non-viral vectors.
10,12,19,20
 Controlled 
polymer-based carriers, the focus of this review, are designed to eliminate or suppress 
repulsive electrostatic interactions between double stranded siRNA and the cellular 
6 
 
 
surface.
8,26,28
  The formation of interpolyelectrolyte complexes (IPECs or polyplexes) 
between therapeutic RNA and cationic polymer segments, not only accomplishes this, but 
also may induce compaction of longer dsRNA while conferring protection from 
endonucleases encountered in RNAi.  Cellular entry can occur by non-specific or targeted 
polyplex uptake. Wong et al. recently reviewed several pathways for endocytic uptake in 
polymer-mediated gene delivery: phagocytosis, macropinocytosis, clathrin-mediated 
endocytosis, caveolae-mediated endocytosis, and clathrin- and caveolae-independent 
endocytosis.
19
  Although all of the above result in enclosure of the polyplexes within 
transport vesicles formed from the plasma membrane, subsequent trafficking and 
processing modes are different and the factors determining the specific pathway are not 
well elucidated at this point. Most studies so far have dealt with DNA, and there are 
likely to be differences between DNA and siRNA polyplex internalization based on size 
and interpolyelectrolyte registry. However, there are some structural similarities that may 
be identified. In general, non-specific endocytosis can be triggered by (a) charge-
mediated interactions of cationic polyplexes with sulfated or carboxylated glucosamine 
residues on membrane-bound proteoglycans and/or (b) hydrophobic associations of 
lipophilic residues on the complex with the phospholipid layers of the cell membrane.
19,28
  
Recently, cell penetrating peptides, 5 to 40 amino acids in length with amphipathic and 
cationic segments have shown potential for binding polynucleotides and facilitating 
membrane translocation.
30
  These peptides may enter non-specifically into the 
phospholipid membrane by several postulated mechanisms including: formation of 
peptide-lined pores, direct penetration, transient uptake, and induced endocytosis.
30
   
 Targeted delivery is accomplished by incorporating ligands that bind to receptors 
on the cell surfaces.  Receptor-mediated targeting and delivery of therapeutics to specific 
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cell lines has been widely studied utilizing a plethora of targeting ligands including 
endogenous folate and transferrin and exogenous peptides, glycoproteins, and 
antibodies.
21,28,29
  To date, however, only a few of these have been reported for targeted 
delivery of siRNA utilizing CRP carriers.
22,23,25
 
 Once cellular uptake has occurred, the resulting polyplex-bearing vesicle may be 
recycled to the surface, routed to cellular organelles, or participate in the endo-lysosomal 
pathway.
28
  As illustrated in Figure 3, the polyplex must escape the endosome vesicles 
before the latter mature to lysosomes in order to avoid enzymatic degradation.  The 
maturation of the early endosomes to lysosomes is accompanied by a pH reduction from 
~6 to ~5.
22
  As such, polymers with pH responsive amine segments (pKa values from 5 to 
7) have been utilized in the polyplex to act as a “proton sponge.”  Protonation results in 
osmotic swelling and disruption of the endosome and release or “escape” of the polyplex 
to the cytoplasm.
22,28
  Peptides that undergo coil-to-helix transformations as pH is 
lowered have also been conjugated to polymeric carriers to induce disruption of the 
endosomes.
21,23,25
  After endosomal escape, polyplex dissociation must occur in order to 
enter the RNAi pathway.
28
  Reduction of strength of interpolyelectrolyte complexes has 
been the most common method of choice to date. Polymer architecture (linear, star, 
dendrimer, branched, etc.), registry and spacing of charges, molecular weight, 
amphiphilicity, reversible cross-linking and other structural characteristics can, in 
principle, be altered to effect facile dissociation.
21–23,28
  
 While many laboratory and clinical studies have reported remarkable advances in 
nucleic acid delivery using both classical polymers and those with designed, precise 
architectures, there is a clear need for tailored siRNA delivery vehicles that are dynamic, 
responding to in situ stimuli encountered in delivery to specific cell types.  Given the 
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large number of structural variables and possible cellular interactions identified in the 
literature to date, Roth
28
 has proposed an “integrated mathematical modeling” approach 
to rational design of delivery vehicles. His approach involves development of kinetic 
models of antisense and siRNA silencing by first describing oligonucleotides and their 
targets in discrete locations or ”compartments” within the cells. Differential equations 
based on conservation of mass are then derived for each of the relevant species, for 
example polymer-bound, free, and mRNA-hybridized siRNA in either endosome or 
cytoplasmic environments. Roth has typically employed 10 species and 20 parameters, 
the latter measure or derived from literature reports, to develop his models. Some 
knockdown experiments in specific cell lines appear to validate these models.
30
 
Successful implementation of such approaches can be anticipated in the future and will be 
aided by rapidly evolving analytical methods capable of elucidating cellular entry and 
trafficking mechanisms.   
Controlled Radical Polymerization (CRP) and Therapeutic Vehicle Design 
 Carrier vehicles designed with criteria consistent with the Ringsdorf “depot” 
model, previously introduced and shown in Figure1, possess essential modular 
components: a water-soluble or amphiphilic polymer backbone, therapeutic agent binding 
sites, and pendent targeting and/or diagnostic moieties. Initial progress toward optimal 
design based on such models was restricted by the absence of sufficiently facile 
polymerization techniques affording control over molecular weight, molecular weight 
distribution, placement of structo-pendent or structo-terminal reactive functional groups, 
polymer architecture (blocks, stars, etc.), and solubility. As controlled radical 
polymerization (CRP) techniques, including stable free radical polymerization (SFRP),
30
  
atom transfer radical polymerization (ATRP),
31
  and RAFT
32–34
 have evolved during the 
9 
 
 
last few years, additional tools for rational design of delivery vectors with the above 
requisite parameters have become available. RAFT and more specifically its aqueous 
counterpart aqueous reversible addition-fragmentation chain transfer (aRAFT)
4,5,35
 are 
arguably the most relevant of the known CRP techniques for preparing delivery vehicles 
for use in biological fluids.  Not only are these particularly versatile for polymerizing a 
wide range of charged and reactive monomers, in many cases polymerization, 
conjugation, therapeutic loading, targeted delivery, and stimuli-responsive release can all 
be accomplished directly in aqueous media.
35
  
 
 
 
Figure 4.  Key steps in formation of homo- and block copolymers via RAFT 
polymerization. 
 
 
 Key steps in the RAFT polymerization process, first proposed by the CSIRO 
group
2
 and later adapted specifically for water,
4,5
 are shown in Figure 4 in order to 
illustrate the method’s utility for synthesizing modular, water-soluble therapeutic delivery 
vehicles discussed in this review.  RAFT polymerization is a degenerative chain transfer 
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process that begins in step I, Figure 4 when an initiator, for example a water-soluble 
diazo initiator, decomposes to yield a primary radical, R•, which then adds to a water-
soluble monomer 1.  In step II, a chain transfer agent (CTA), a thiocarbonylthio 
compound, reacts with the primary oligomeric radical to produce an intermediate radical 
that subsequently eliminates R• which in turn adds to monomer 1.  The CTA is key to 
control of molecular weight and ”livingness“ of the RAFT process and various 
thiocarbonylthio species including dithioesters, xanthates, dithiocarbamates, and 
trithiocarbonates have been utilized.
32–34
  The degree of stabilization of the intermediate 
radicals in steps II and III of Figure 4 depends on the nature of Z as does the rate of R• or 
kinetic chain scission from the intermediate for subsequent addition to monomer 1. 
Active (propagating) radicals eventually reach equilibrium with dormant chains, termed 
macroCTAs.  The reversible nature of the degenerative process, the equilibrium favoring 
the dormant chains, and the apparent inability of the intermediate radical to add to 
monomer result in the polymerization having a “living” nature with degree of 
polymerization increasing linearly with conversion. MacoCTAs can be extended, for 
example, by the sequential addition of a second water-soluble monomer as shown in step 
III of Figure 4, resulting in the formation of stimuli-responsive block copolymers.
7,35
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Figure 5.  Varying architectures from CRP techniques amenable to siRNA binding. 
 
 
 An important advantage of RAFT and other CRP polymerization techniques is the 
ability to prepare well-defined polymers with specified architectures (Figure 5).  Of 
interest to siRNA therapeutics are diblock, triblock, brush, and star architectures prepared 
from amine-functional monomers that can be synthesized via aRAFT directly in water 
without the need for protecting groups.
7
  R and Z functionality can be altered to allow 
structural variation as well as facile post-polymerization reactions.
35
  The nature of the 
segments and the molecular weight-dependent hydrodynamic volume under aqueous 
conditions, in principle, can be critically controlled by selecting from a wide variety of 
water-soluble monomers,
7,35
 designing CTAs and their conjugates,
36
 and specifying the 
monomer/CTA ratios.
7,33–36
  As detailed later, packaging and protection from enzymatic 
degradation have recently been accomplished by direct, molecular level complexation of 
siRNA with specified segments (for example those with cationic charges) or those 
presented on nano size, self-assembled complexes (e.g., micelles, vesicles, polymersomes 
and their conjugates and crosslinked versions).  As mentioned previously, secondary and 
tertiary amine-containing segments are thought to elicit endosomal disruption and 
polyplex release by taking advantage of the “proton sponge” or buffering effect.  For 
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example, interpolyelectrolyte complexes between siRNA and PDMAPMA (poly(3-(N,N-
dimethylamino)-propyl methacrylamide)) (or other protonated tertiary amine segments of 
block copolymers)
37–44
 can be prepared with varied nitrogen-to-phosphate (N/P) ratios, 
affecting not only solubility but also cell entry by non-specific endocytosis and eventual 
release from the endosome.  Neutral, water-soluble monomers such as N,N-
dimethylacrylamide (DMA)
45–48
 or N-(2-hydroxypropyl)-methacrylamide (HPMA)
14,49–62
 
can be copolymerized statistically or as blocks in order to maintain water solubility and 
prevent rapid clearance from the blood stream.  Amphiphilicity can be adjusted by adding 
hydrophobic monomers (e.g., butyl acrylate
38,39,63
) or those responsive to temperature (N-
isopropylacrylamide (NIPAM))
64
 or pH (secondary and tertiary amine-containing 
monomers).
37–44
  AB diblock or ABA triblock systems of the type, shown in Figure 5, can 
be prepared utilizing dithioester or trithiocarbonate CTAs that have near-perfect end 
group functionality since the R group of the initiator and that of the CTA are identical.  
Such telechelic end groups can play important roles in attaching moieties for targeted 
delivery or for attaching diagnostic agents.  Reactive functionalities, such as active esters, 
exchangeable disulfides, and primary amines, can also be readily accommodated by 
copolymerizing functional monomers via RAFT.
7,35
  A number of recent papers and 
reviews discuss facile chemical or bioconjugation methods utilizing reactive monomers 
or CTAs with appropriate functionality (Figure 6).
13,42,65–71
  Notable milestones allowing 
the construction of delivery vehicles were the first controlled polymer syntheses by 
Scales, Convertine, York et al. of the hydrophilic monomers DMA, HPMA, NIPAM and 
the protonated (cationic) DMAEMA, DMAPMA, and APMA monomers (Figure 6) via 
aRAFT polymerization.
45,52,72,73
  Though beyond the scope of this chapter, the reader is 
referred to recent reviews of post-polymerization modification methods including 
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orthogonal “click” chemistries which have been or can potentially be utilized in 
delivery.
66,74–89
  
Linear Polymer Vehicles 
 Literature reports of linear homopolymers with controlled structures utilized for 
gene delivery are almost exclusively on P(DMAEMA) synthesized via RAFT or 
ATRP.
90–97
  However, as previously mentioned, complexes must be cationically-charged 
overall to maintain particle dispersion.  Although this and favorable interactions at the 
cell surface promote uptake, problems of nucleotide release from the interpolyelectrolyte 
complex later in the process affect efficiency of delivery.
98,99
 
 
 
 
Figure 6.  Reactive monomers and functional groups utilized for delivery vehicles 
prepared via RAFT Polymerization. 
 
 
 Perhaps the most widely studied systems for the delivery of siRNA have been 
block copolymers comprised of hydrophilic and cationic segments.
98,100–102
  These 
copolymers can form near-neutral interpolyelectrolyte complexes with negatively charged 
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siRNA and have the added benefit of remaining soluble and stable in solution.  However, 
while the hydrophilic block can increase stability/shielding and circulation time, it has 
also been shown to decrease uptake as compared to its positively charged 
counterparts.
98,103
  To combat this problem, York et al. utilized targeting entities for 
receptor-mediated endocytosis.
42
   Copolymers containing a cationic block of DMAPMA 
and a hydrophilic block of HPMA-s-APMA were synthesized for siRNA delivery (Figure 
7). The APMA (N-(3-aminopropyl)methacrylamide hydrochloride) monomer has primary 
amine functionality for attaching a targeting group.  These monomers were polymerized 
under buffered, aqueous RAFT conditions yielding copolymers of ~ 50 kDa with narrow 
polydispersity index (PDI) values of ~1.1.  Folic acid, a well-known and extensively 
studied targeting group moiety,
104–108
 was conjugated to the polymers via post-
polymerization modification of the primary amines of APMA with efficiencies of > 80 %.  
The resulting targeted copolymer was then complexed with siRNA to yield near-neutral 
sterically protected complexes ~ 15 nm in diameter.  These complexes were incubated 
with cell lines that expressed both high levels (KB cells) and low levels (A549 cells) of 
folic acid receptors.  The targeted complexes showed high selectivity for KB cells and 
60% knockdown of the gene coding for human Survivin. 
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Figure 7.Poly[ (HPMA-statistical-APMA)-block-DMAPMA] copolymers complexed 
with siRNA for targeted gene delivery.
43
 
 
 
 Folic acid serves as an excellent moiety to serve as a cellular targeting group, but 
there have been a few methods which utilize an alternative approach to promote cellular 
recognition. Utilizing a PEG macroCTA, Schultz and coworkers prepared poly(GPMA) 
which incorporated FAB antibody fragments at the α-terminus. These fragments targeted 
the HER2 receptor, a member of the epidermal growth factor family that is overexpressed 
in one-third of breast cancers, and cellular recognition was increased by 10-fold. As a 
consequence, a major reduction in mRNA and protein levels (> 90%) was achieved. 
Alternatively, mannose and cholesterol have been conjugated to RAFT synthesized block 
copolymers, and while these targeting ligands promoted efficacious delivery, these 
systems warrant further insight as the design of these systems provides methods to 
overcome additional barriers (vide infra). 
 One of the most significant bottlenecks in the delivery of siRNA to cells is release 
from endosomal compartments after uptake.
16,109–111
  One strategy has focused on the 
post-polymerization conjugation of endolytic agents to the hydrophilic block of these 
copolymers.
111
  However, even with the advent of facile and quantitative chemistries in 
recent years,
75,78,84,88,112,113
 such post-polymerization modifications involving 
macromolecular species can be inefficient and produce undesired by-products.  Both 
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quantifying yields and product characterization can prove difficult.
114
  Therefore, direct 
polymerization of CRP monomers capable of undergoing stimuli responsive transitions to 
“unmask” endolytic properties, such as proton sponges or hydrophobic, membrane-
disrupting moieties, is an attractive approach. 
 Convertine et al. designed an endolytic copolymer delivery system that contained 
a block of 2-(N,N-dimethylamino)-ethyl methacrylate (DMAEMA) for complexation 
with siRNA and an ampholyte block containing butyl methacrylate (BMA), DMAEMA, 
and poly(propylacrylic acid) (PAA) to act as both a shielding/stabilizing and pH-
responsive block.
39
  The RAFT- synthesized terpolymers ranged in molecular weight 
from 16 kDa to 20 kDa with moderate PDIs (1.45–1.58).   Despite the statistical nature of 
the hydrophobic block, DMAEMA and PAA were chosen to be 1:1 for neutrality, while 
BMA was varied to modify hydrophobic content.  At physiological pH, no higher ordered 
structures were formed prior to the addition of siRNA.  At N:P ratios of 1:1, only large 
aggregates were identified by dynamic light scattering (DLS), with a reduction in particle 
size at increasing charge ratios.  Particle sizes ranged from 85–236 nm with the highest 
BMA content (48 mol%) giving rise to the smallest particles at N:P ratios of 4:1.  Despite 
the higher nitrogen content, surface charge of these particles remained near neutral.  The 
endolytic activities of these copolymers and IPECs were investigated using a red blood 
cell hemolysis assay at varying pH values, representing physiological conditions, early 
endosome, and late endosome.  At physiological pH, no endolytic activity was observed 
due to the charge neutrality of the ampholyte block.  Polymers containing the most BMA 
content demonstrated the greatest degree of hemoglobin release at both early and late 
endosomal pH.  Upon acidification of the endosomal compartment, it is predicted that the 
carboxylic acid residues are protonated, resulting in a more hydrophobic block with an 
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overall net positive charge that is likely to interact with the membrane.  Knockdown of 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase – an enzyme that catalyzes 
glycolysis and is implicated in several non-metabolic processes, including transcription 
activation, initiation of apoptosis and ER to Golgi vesicle shuttling) was investigated in 
HeLa cells and ranged between 50–80 % depending on the polymer and formulation.   
 They have further modified these systems to maintain endosomolytic capability, 
but also, to produce polymeric carriers that offer neutral delivery of siRNA.
115
 A thiolated 
siRNA targeting GAPDH was conjugated to poly[HPMA-co-PDSMA)-block-(PAA-co-
DMAEMA-co-BMA)] (Figure 8) via a pendent disulfide exchange in the PDSMA block. 
The second block confers endosomolytic capability, and siRNA release occurs via 
intracellular reduction with glutathione. Under optimized conditions, a 90 % reduction in 
mRNA and a 60 % reduction in protein levels were achieved after 48 h. These researchers 
have been prolific in designing these systems, and many reports utilize the 
PAA/DMAEMA/BMA combination to achieve endosomal escape. 
 
18 
 
 
 
 
Figure 8. Preparation of poly[(HPMA-co-PDSMA)-b-(PAA-co-DMAEMA-co-BMA)] 
polymeric carriers for neutral delivery of siRNA.
115
 
 
 
 While most polymeric vehicles are designed to overcome delivery barriers, only 
one report focuses both on delivery challenges as well as economic viability. Reineke and 
coworkers
116
 prepared poly(trehalose-b-AEMA) copolymers, and the rationale behind 
these constructs was to solve long-term storage of siRNA-polymer complexes. Trehalose, 
a disaccharide consisting of glucose, protects cells during oxidative stress and freezing, 
and it aids in cryptobiosis. The primary amine block AEMA serves to bind siRNA, while 
the trahalose segments confers long-term stability. Copolymer-siRNA complexes were 
reported to retain potency after lyophilization as demonstrated via luminescence assays 
on U-87 cells containing Gaussia Luciferase. Modest gene knockdown was observed for 
these systems (~ 60% reduced protein expression), but the fact that these systems 
remained active after long-term freezing (1 month) is remarkable. 
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Polymer Micelle Vehicles 
 The complexation of siRNA with cationic polymers results in spontaneous 
assembly of IPECs.  It is known from the literature that the resultant size and distribution 
of these complexes is highly dependent upon the length of the charged segments, the total 
length of the polymer, and the conditions under which they are prepared.
7,117–124
  Scales et 
al. have shown that in particular instances, a single siRNA molecule can be surrounded 
by multiple polymers, significantly limiting the therapeutic loading of these types of 
vectors.
41
  Ideally, the incorporation of multiple siRNAs per polymer complex is 
desirable to increase the therapeutic efficiency while maintaining control over the size, 
shape, and distribution of the carrier. 
 One way to accomplish this is by the formation of the vehicle before loading the 
therapeutic agent.  The formation of well-defined micelles and vesicles from polymers 
prepared via controlled polymerization methods is well established.
7,67,73,100,117–122,124–140
  
In addition to allowing for control over the size and size distribution of the vehicle, the 
use of micelles/vesicles as gene delivery vehicles also can mitigate toxicity.  Typically 
cationic (co) polymers exhibit in vitro toxicity that increases with molecular weight and 
cationic charge density, both of which also increase complexation and gene knockdown 
ability.  Utilizing lower molecular weight components, higher ordered structures can 
degrade/dissociate into less toxic components.  Though limited by the dynamic nature of 
such associated entities, it has been reported that the use of nucleic acids as crosslinking 
polyanions can result in sufficiently stable complexes.
38,43,63,100,122,137
  
 In an extension of the work by Stayton and coworkers mentioned previously, 
micelles capable of complexing with siRNA in the corona while containing an endosomal 
release component in the core were prepared via RAFT polymerization.
38
  The corona 
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consisted of DMAEMA while the core block was composed of statistically incorporated 
BMA, PAA, and DMAEMA (Figure 9).  The hydrophobic block was synthesized to be 
approximately 2.5 times larger than the hydrophilic block, and the optimum incorporation 
of BMA was found to be approximately 50% in the hydrophobic block.  Particle sizes of 
the resulting micelles were 45 nm at pH 7.4, and upon the addition of siRNA (N:P = 4), 
particle sizes remained fairly consistent at 47 nm. 
 
 
 
 
Figure 9.  RAFT synthesis of hydrophilic, cationic DMAEMA macroCTA and 
subsequent chain extension for the preparation of an endolytic and polyampholyte block 
(which incorporates DMAEMA, PAA, and BMA).
39
  
 
 
 Membrane destabilizing ability was investigated using a red blood cell hemolysis 
assay.  Three pH conditions were chosen to mimic cellular internalization:  pH = 7.4 
(extracellular), pH = 6.6 (early endosome), and pH 5.8 (late endosome).  No significant 
hemolytic activity was observed at pH 7.4, while decreasing pH below 7.4 resulted in 
increasing hemolytic activity.  siRNA was complexed at various N:P ratios to account for 
any change that might be displayed in hemolytic activity due to charge-charge 
interactions, and none was observed even at high N:P ratios (N:P = 8).  Additionally, 
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differences in hemolytic activity between linear and assembled polymer solutions were 
negligible.  Gene knockdown experiments were performed in HeLa cells with varying 
polymer (above and below the critical micelle concentration) and siRNA concentrations 
(12.5 nM–100 nM).  The greatest knockdown was observed with micelles at the highest 
siRNA concentrations, <90%.  Investigation of uptake using FAM-labeled (6-
carboxyfluorescein) siRNA revealed that almost 100% of cells were transfected by 
micelles, compared to only 25% in the previous study with the linear polymer system.
38  
 Monteiro and coworkers
141,142
 prepared micellular nanocarriers which would self-
catalyze their own degradation.  Utilizing aRAFT, poly[DMAEMA65-block-(ImPAA45-
co-BA29)] copolymers (Figure 10) were prepared that served two functions: endosomal 
escape and “timed” siRNA release. The first block contains DMAEMA, which self-
catalyzes hydrolysis, forming poly(acrylic acid), and this block was tuned to promote 
siRNA release over the course of 48 h. The release of siRNA is maximized via the 
“charge-shifting” approach; which takes advantage of charge repulsion between ionized 
poly(acrylic acid) and the anionic phosphodiester backbone of siRNA. The second block 
promotes endosomal fusion and subsequent escape. The ImPAA and BA moieties behave 
similarly to the influenza virus, promoting endosomal escape via membrane disruption. 
The siRNA delivered targeted PLK1, a kinase that maintains tumorgenic phenotypes of 
osteosarcoma cells, and utilizing these block copolymers, upwards of 98 % cell death was 
reported. Furthermore, owing to the degradability of DMAEMA, these polymeric carriers 
exhibited negligible toxicity, even at polymer concentrations > 300 μg/mL.  
 Seeking to utilize the advantageous degradability of DMAEAMA, these 
coworkers,  prepared polymeric carriers with a star architecture.
143
 These star systems 
were prepared via chain extension of a DMAEMA macroCTA with a statistical 
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incorporation of bis-N,N-(acryloyl) cysteine and DMAEMA. These systems were shown 
to be nontoxic and biodegradable under physiological conditions. siRNA was delivered to 
two different cell lines: pancreatic cells (MiaPaCa-2-Luc2) and lung cancer cells *H460 
NSCLC). Approximately 80% reduction in mRNA and protein levels were observed in 
the lung cancer cell line; however, delivery to pancreatic cells was less efficient with 
~50% and ~60% reduction in mRNA and protein levels, respectively. Furthermore, these 
star systems demonstrated mild success in vivo with a 60% reduction in mRNA levels in 
mice exhibiting lung cancer (H460).  
 
 
Figure 10. Preparation of poly[DMAEMA-b-(ImpAA-co-BA)] copolymers. These 
constructs contain a self-catalyzing mechanism that promotes siRNA release and an 
endosomolytic block.
143
 
 
 
 The use of higher ordered structures such as micelles and vesicles also present the 
additional option of incorporating multiple therapeutic agents.  Micelles with 
hydrophobic cores can accommodate poorly-soluble drug payloads, while vesicles with 
hydrophilic cores can accommodate water-soluble drugs.  Taking advantage of this 
option, Park and coworkers prepared biodegradable cationic micelles for co-delivery of 
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siRNA and paclitaxel.
44  ε-Caprolactone was polymerized (7 kDa, PDI = 1.26) and 
subsequently N,N'-dicyclohexylcarbodiimide (DCC)-coupled to 4-cyanopentanoic acid 
dithionaphthalenoate (CPADN) to prepare a macroCTA for RAFT polymerization of 
DMAEMA (Figure 11).  Molecular weights ranged from 9.1 kDa to 21.1 kDa with PDIs 
ranging from 1.15–1.42.  Micelles were prepared by direct dissolution into HAc-NaAc 
buffer (pH = 5.0) overnight and had CMC values of 15.8–24.0 mg/L.  Particle sizes 
ranged from 54 nm to 132 nm, and possessed moderately positive surface charges (+29.3 
mV to +35.5 mV).  Complexation with siRNA was investigated using a gel retardation 
assay, and complete retardation was observed at N:P> 4:1.  siRNA transfection was 
monitored in MDA-MB-435-GFP cells.  The experiments were carried out utilizing N:P 
= 36:1 and N:P = 12:1 for the micelles, with PEI (poly(ethylene imine)) (25 kDa) and 
DMAEMA homopolymers utilized as positive controls.  The micelles had much higher 
transfection ability as compared to the positive controls.  Cytotoxicity of the micelles was 
investigated in PC3 cells.  The micelles were loaded with paclitaxel (6.8 wt%), and 
possessed a higher drug efficacy than free paclitaxel which the author attributed to 
enhanced endocytosis of the micelles.  Cells incubated with the free drug had viabilities 
of around 70%, whereas cells incubated with drug-loaded micelles had viabilities of 
approximately 50%, independent of the micelle concentration used.  Co-delivery was 
investigated in PC3 cells with paclitaxel-loaded micelles complexed with siRNA at N:P = 
24.  Co-delivery resulted in 90% down-regulation of VEGF (vascular endothelial growth 
factor) expression whereas branched PEI exhibited 75% down-regulation.  Interestingly, 
co-delivery of the therapeutic agents was slightly more efficient (90% vs. 80%) than 
micelle delivery of siRNA alone. 
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Figure 11. Synthetic pathway for the preparation of Poly(DMAEMA-block-CL-block-
DMAEMA) degradable copolymers.
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Stayton and coworkers have also developed a multitherapeutic micellar system 
consisting of doxorubicin, an anthracycline utilized in many cancers, and siRNA against 
plk1, which has been shown to cause cell-cycle arrest and apoptosis in cancer cell lines as 
well as increased sensitivity to chemotherapeutics.
63
  The complexes they report consist 
of three basic components:  (1) cationic micelles composed of P(DMAEMA-b-BMA) 
diblock copolymers (pDbB), (2) siRNA, and (3) anionic, pH-sensitive poly(styrene-alt-
maleic anhydride) (pSMA) polymers that mediate endosomal escape (Figure 12).  pDbB 
was synthesized via RAFT using dodecyl cyanovalerictrithiocarbonate (DCT) CTA and 
2,2’-azobis(2-methylpropionitrile) (AIBN) radical source.  The overall Mw of the 
copolymer was 9.4 kDa with a PDI of 1.2.  The pSMA was also synthesized via RAFT 
using 4-cyanopentanoic acid dithiobenzoate (CTP) and AIBN.  A Mw of 48.5 kDa was 
targeted based on endolytic activity from previous studies.
144
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Figure 12.  Ternary complex formation: siRNA (red), Poly(BMA) (black), Poly(D-block-
B) (purple), and Poly(SMA) (blue).
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pDbB can form micelles at pH 7.4 such that the protonated DMAEMA block acts 
as the corona and the hydrophobic BMA block serves as the hydrophobic core.  These 
micelles are positively charged with mean diameters of 37 nm.  Both anionic siRNA and 
pSMA can be used to complex with the positively charged DMAEMA corona.  
Depending on the ratio of the three components, micelles with diameters varying from 
30–100 nm can be obtained, all maintaining a solution- stable, slightly positively charged 
complex (zeta potentials ranging from 0–1.2 mV).  Micelles could be co-loaded with 
doxorubicin up to 10 wt% with a slight increase in micelle size.  The gene knockdown 
ability and cell viability towards doxorubicin were investigated in both drug-sensitive 
OVCAR8 and multidrug-resistant NCI/ADR-REDS ovarian cancer cell lines.  The 
ternary micelle complexes were able to achieve ~50% knockdown (with or without 
doxorubicin) and effectively sensitized drug-resistant cells to doxorubicin resulting in a 
decrease in cell viability comparable to drug-sensitive cells.
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Polymer-Inorganic Hybrid Carriers—Theranostics 
 Clearly the advent of controlled radical polymerization techniques has led to the 
dramatic increase in use of polymers for the construction of gene delivery vehicles. Still, 
many other materials have also found use in this burgeoning area.  Calcium phosphate,
145
 
silica nanoparticles,
146–148
 and carbon nanotubes
149–152
 are just a small sampling of the 
many inorganic substrates that have been used in recent years as transfection agents.
153,154
  
Indeed, the use of inorganic nanoparticles has proliferated due to their ease of synthesis, 
wide range of sizes, and biocompatibility.
155–158
  However, the application of simple 
inorganic nanoparticle constructs has been hindered due to their instability/aggregation, 
low loading efficiencies, and lack of functional “handles” for targeting group 
incorporation.
158
  
 Initially, the placement of polymers onto metal nanoparticles was attempted to 
address issues of stability and the incorporation of reactive functionality.
159,160
  These 
early designs utilized ill-defined polymers, most of which were adsorbed onto the metal 
surface.  However, developments in controlled syntheses of polymers as well as inorganic 
nanoparticles have led to the construction of well-defined hybrid materials.  It has been 
through the combination of these materials that the development of “theranostics,” the 
incorporation of therapeutic and diagnostic agents on the same platform, has occurred.
161–
166
  Thus, the combination of inorganic nanoparticles with organic polymers presents a 
class of novel delivery vehicles with enormous potential applications. 
 With recent advances in the synthesis of well-defined, narrowly dispersed iron 
oxide nanoparticles (IONPs), use of this material as both diagnostic agent
167
 and a 
hyperthermia therapeutic has garnered increased attention.
168
  IONPs have also been used 
in the delivery of oligonucleotides via interpolyelectrolyte complexation with ill-defined 
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cationic polymers, such as PEI, adsorbed to their surface.
29
  However, their usefulness in 
vitro/in vivo has been limited due to instability, aggregation, and fouling of the 
nanoparticle surface.  Boyer and Davis have been able to combat this problem by 
developing a “grafting to” process utilizing polymers synthesized via RAFT containing a 
phosphonic acid end group that has a very high affinity for iron
169
 (Figure 13).  The 
phosphonic acid is coupled to a CTA utilized in the preparation of the polymers and ends 
up as a telechelic group on the terminus of the polymer chain.
170
  In their most recent 
work, Boyer et al.
170
 have shown that by “co”-grafting two homopolymers, a cationic 
PDMAEA (Poly(2-(N,N-dimethylamino)-ethyl acrylate)) and a hydrophilic POEGA 
(poly(oligo(ethylene glycol) acrylate)) onto the surface of pre-formed IONPs. The 
grafting density (0.12 chains/nm
2
) can be greatly increased over grafting homopolymer 
(PDMAEA 0.07 chains/nm
2
) or even a diblock copolymer (0.06 chains/nm
2
) alone.  This 
increased grafting density has direct correlation to the overall stability of the NPs, making 
them storable for months instead of days, and highly resistant to protein absorption.  
Proton transverse relaxivity rates of bare NPs were compared to polymer grafted NPs and 
showed no marked effect.  The gene knockdown of eGFP (green fluorescent protein) in 
human neuroblastoma cells of these constructs was investigated using flow cytometry.  
Compared to the lipofectamine control (40%), the fluorescence intensity of cells 
incubated with the co-graft IONPs was 78%, which was attributed to decreased uptake 
due to pegylation of the particles.  Interestingly, application of a magnetic field, which 
has been shown to effect the uptake of magnetic nanoparticles in cells,
171
 had a dramatic 
effect on the transfection efficiency, decreasing the fluorescence intensity to 50%, only 
slightly higher than the lipofectamine control. 
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Figure 13.  A graphical representation demonstrating (A) simultaneous grafting of two 
homopolymers, and (B) grafting of diblock copolymers.
157 
  
 
 
Perhaps the most successful and widely used inorganic platform is gold.  
Inherently non-toxic and inert, gold nanoparticles (GNPs) are easily synthesized in a 
range of sizes, easily functionalizable, and readily taken up by most cell lines.
172–182
  Gold 
nanoparticles have also recently been approved by the FDA as formulated in the X-ray 
contrast agent, AuroVist™, and have the added benefit of functioning as a diagnostic 
agent.
183,184
  While the functionalization of gold nanoparticles with polymers has been 
widely demonstrated to increase therapeutic loading,
185
  incorporate targeting,
186–188
  and 
increase circulation time and stability in vivo,
189
 the construction of these platforms has 
been limited by low polymer grafting density due to inefficient ligand exchange.  
McCormick and coworkers have recently reported the synthesis of polymer-decorated 
gold nanoparticles that are formed in situ by the reduction of gold aurate by amine-
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containing blocks on their RAFT polymers.
40,134,190,191
  In particular, P(HPMA-b-
DMAPMA) synthesized via aqueous RAFT was used to form and stabilize siRNA 
polyplexes (Figure 14).
40
  The size and dispersity of these particles prior to IPEC 
formation with siRNA can be controlled by varying conditions including substrate 
concentration, amine to gold ratios, polymer block lengths, and reaction temperature.  
The grafting densities of the polymer-stabilized GNPs was quite high, 2.7 chains/nm
2
, as 
compared to similar systems, likely due to the extended conformation adopted by the 
polymer chains on the gold surface which also leads to larger diameter particles (29 nm) 
than predicted for random-coils (14 nm).  The sizes of the GNPs before siRNA 
complexation were determined by TEM to be ~ 6.5 nm.  It should be noted that for the 
complexes shown in Figure 14, the siRNA is protected against degradation by nucleases 
through both steric shielding conferred by the  HPMA shell and  by interpolyelectrolyte 
complexation with the protonated segments of the polymer vector.  Luciferase expression 
was used to determine transfection efficiency of these constructs in KB cell lines.  In 
these studies, polymer-stabilized GNPs demonstrated identical knockdown (50%) as the 
commercial agent Dharmafect.  
SiRNA-Polymer Conjugates 
 Most research on siRNA delivery has focused on the formation of 
interpolyelectrolyte complexes with cationic polymers.  However, many questions still 
remain concerning the binding strength of these complexes, the mechanism of siRNA 
release, and how these parameters affect gene knockdown 
efficiency.
8,10,16,19,21,23,25,26,28,29,122
  A number of barriers to delivery might be overcome by 
designing better therapeutic carriers utilizing modular concepts introduced by the original 
Ringsdorf model, for example utilizing cleavable functionality to release siRNA. 
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Figure 14.  Reduction of Au  in the presence of Poly(HPMA-block-DMAPMA) 
copolymers to form hydrophilic-block-cationic AuNPs and subsequent complexation of 
siRNA.
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Much effort in the conjugation of biomolecules to RAFT polymers has focused on 
modification of the chain ends via functionality incorporated from the R or Z groups of 
the CTA agent (Figure 6).
53,66,71,192–200
  However, to be applicable to the delivery of 
siRNA,the conjugation used must be reversible/cleavable.  Bulmus and Maynard have 
several examples of reversible conjugation to the terminus of polymers via a disulfide 
linkage.
44,192,193,196,200,201
  Perhaps the most promising for delivery was conjugation of 
siRNA to a water-soluble poly(ethylene glycol)-containing acrylate utilizing elegant 
RAFT chemistry. 
196
  Simple conjugation of poly(ethylene glycol) (PEG) to siRNA via a 
disulfide bond has been shown to both increase the circulation time and protect against 
premature degradation.
202–204
  Pyridyl disulfide propanol was coupled to the CTA 2-(ethyl 
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trithiocarbonate)propionic acid and used to polymerize poly(ethylene glycol) acrylate 
(PEGA) (Figure 15).  Linear kinetic plots were obtained in DMF at 60 
o
C with AIBN as 
an initiator after a 20 m inhibition period.  Conversions up to 80% with PDIs approaching 
1.2 were obtained.  Retention of the end group was confirmed by 
1
H NMR.  Thiol 
exchange between the 5’-end of the siRNA and the pyridyl disulfide was accomplished 
with 88% yield.  Complete cleavage of siRNA could be achieved under reductive 
conditions with dithiothreitol (DTT). 
 
 
Figure 15.  Synthesis of a pyridyl disulfide functionalized CTA and subsequent RAFT 
polymerization of PEGA.
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 This thiol exchange strategy, developed by Bulmus and coworkers initially for 
protein conjugation to RAFT polymers,
193
  was also utilized by York et al. for 
conjugation of siRNA to RAFT polymers at multiple sites along the backbone.
70
  Instead 
of conjugating one siRNA per polymer, they were able to incorporate multiple siRNAs to 
increase the therapeutic payload and potentially increase the efficiency (Figure 16).  
HPMA was copolymerized with APMA using V-501 (4,4’-azobis(4-cyanovaleric acid)) 
as the initiator and CTP as the CTA.  The final polymer was end-capped with AIBN due 
to the potential toxicity of the CTA end group.
205
 N-succinimidyl 3-(2-pyridyldithio) 
propionate (SPDP) was used to functionalize the free amines of the APMA.  Thiol 
exchange with the sense strand of the siRNA was accomplished with 89% efficiency.  
Folic acid was then conjugated to the remaining free amines for targeting.  The anti-sense 
strand was subsequently complexed to the polymer conjugate.  Release of siRNA from 
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the polymer was demonstrated under intercellular conditions with 5 mM glutathione.  
About 60% of the siRNA was released in a 4 h period. 
 
 
 
 
Figure 16.  Reaction pathway for the synthesis of both RNA and folate conjugated 
copolymers and subsequent hybridization with RNA antisense strands.
70
 
 
 
 This chapter has focused on utilizing RAFT polymerization to prepare constructs 
for drug/gene delivery applications. In principle, these carriers were rationally designed 
to overcome hurdles in achieving efficient delivery of siRNA. While these systems 
succeeded in their stated objectives, the focus was on developing “novel” polymeric 
carriers and not elucidating underlying structure-behavioral relationships governing 
efficient and efficacious delivery. This dissertation seeks to elucidate such underlying 
structure-property relationships, providing further insight in the rational design of 
polymeric drug/gene delivery carriers. 
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CHAPTER II 
OBJECTIVES OF RESEARCH 
 While ideas for efficacious drug/gene delivery have been in circulation for many 
years, techniques for achieving successful delivery have only recently emerged. 
Specifically, reversible addition-fragmentation chain transfer (RAFT) and its aqueous 
counterpart aRAFT. This polymerization method allows for facile preparation of 
(co)polymers with tailorable architectures, pre-determined molecular weights, directly in 
water. Serendipitously, small interfering RNA (siRNA), an anticancer biologic, was 
discovered the same year as RAFT. With siRNA, virtually any gene of interest may be 
removed post-transcriptionally. However, delivery of siRNA possesses several barriers: 
reduced cellular uptake due to charge repulsion, lack of cellular specificity, and reduced 
circulation due to rapid clearance. With these challenges in mind, several researchers (see 
Chapter I) as well as the McCormick group, have developed polymeric delivery vehicles 
utilizing the RAFT process which significantly enhance siRNA efficacy in vitro. 
Specifically, polymeric carriers which possess endosomal escape abilities, cell targeting 
functionality, and self-degradative mechanisms have been prepared. Despite these 
advancements, the precise mechanisms of siRNA release and delivery to targeted cells 
have yet to be elucidated. Fundamental insights into the barriers which limit drug efficacy 
must be achieved before true potential can be achieved.  
 This dissertation seeks to ascertain structure-property relationships affecting 
endosomal escape and drug release. Furthermore, this dissertation is divided into three 
sections. The first section describes the synthesis of pH-responsive poly[HPMA-block-
(L-Glu)] copolymers as well as their ability to prompt membrane disruption; these novel, 
endolytic copolymers were specifically designed to address endosomal escape. The 
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second section describes the structure-property relationships involved in complex 
dissociation. A series of hydrophilic-block-cationic copolymers consisting of 
poly[(HPMA-stat-APMA)-block-DMAPMA) were prepared via aRAFT to elucidate a 
pathway for siRNA release, and how this release profile affects gene suppression in vitro. 
The last section investigates the effects on drug efficacy via modifications to 
oligonucleotide secondary structure. A novel therapeutic, AS1411, a G-quadruplex 
forming single-stranded DNA, was utilized since defects in secondary structure are less 
tolerable for this anticancer biologic. Again, hydrophilic-block-cationic copolymers were 
utilized as polymeric carriers to ascertain drug efficacy in vitro. 
 The specific objectives of this research are the following: 
1. Prepare well-defined macroCTAs comprised of HPMA and APMA. 
2. Prepare well-defined hydrophilic-block-cationic copolymers via chain 
extensions of macroCTA with DMAPMA. 
3. Modify HPMA macroCTA via thiol-ene Michael addition for the conversion 
into a macroinitiator. 
4. Prepare pH-responsive, endolytic block copolymers consisting of HPMA and 
γ-benzyl glutamic acid utilizing HPMA macroinitiator. 
5. Characterize all (co)polymers, macroCTAs, and macroinitiators with respect 
to Mw, Mn, PDI, and molar composition utilizing ASEC-MALLS and 1H 
NMR. 
6. Determine coil-to-helix transitions of poly[HPMA-block-(L-Glu)] copolymers 
utilizing a pH-stimulus via circular dichroism. 
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7. Determine structure-property relationships of poly[HPMA-block-(L-Glu)] 
copolymers which promote hemolysis and dye leakage from artificial 
membranes under conditions mimicking the endosome. 
8. Prepare charge neutral block ionomer complexes comprised of an 
oligonucleotide and poly[(HPMA-stat-APMA)-block-DMAPM hydrophilic-
block-cationic copolymers. 
9. Characterize block ionomer complexes with respect to size, charge, and 
structure utilizing dynamic light scattering, ζ-potential, gel electrophoresis, 
and circular dichroism. 
10. Determine structure-property relationships governing binding strength, 
stoichiometry, electrostatic complex dissociation, and gene suppression 
utilizing solution differential scanning calorimetry, analytical 
ultracentrifugation, and relative luminescence.  
11. Ascertain the effects of secondary structure modification of G-quadruplexes 
on drug efficacy delivered by poly[(HPMA-stat-APMA)-block-DMAPMA 
copolymers utilizing circular dichroism, dynamic light scattering, ζ-potential, 
gel electrophoresis, and cell viability. 
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CHAPTER III 
 
EXPERIMENTAL 
 
Materials 
 
All reagents were purchased from Sigma and used without further purification 
unless otherwise noted. N-(3-aminopropyl)methacrylamide (APMA) was purchased from 
Polysciences. 4,4’-Azobiscyanovaleric acid (V-501) (Wako) and azobisisobutryonitrile 
(AIBN) were recrystallized twice from methanol. 4-cyano-4-
[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CEP),
39
 4-cyano pentanoic acid 
dithiobenzoate (CTP),
206
 di-N-hydroxy succinimide activated folic acid (diNHS-FA),
42
  
and N-(2-hydroxypropyl)methacrylamide (HPMA)
207
 were prepared as previously 
reported. N,N-(3-dimethylamiopropyl)methacrylamide (DMAPMA) and triethylamine 
(TEA) were distilled prior to use. HPLC purified oligonucleotides (siRNA against 
Gaussia Luciferase and the dsDNA analogue of siRNA) were purchased from Integrated 
DNA Technologies, Inc. The siRNA sequences targeting Guassia Luciferase are as 
follows: Sense strand 5’-AGAUGUGCAACUUUUGCUACCGCAUCU-3’ and the 
antisense strand 5’-AGGAGAUGCGGUAGCAAAAGUUGCACAUCUUU-3’. The 
DNA analogue sequences of siRNA are as follows: Sense strand 5’-
AGATGTGCAATTTTGCTACCGCATCT-3’ and the antisense strand 5’-
AGGAGATGCGGTAGCAAAAGTTGCACATCTTT-3’. Oligonucelotides (siRNA and 
dsDNA) were heated at 95 °C for 10 min and were allowed to slowly cool to room 
temperature prior to use. Concentrations of oligonucleotide (siRNA and dsDNA) are 
reported as duplex concentrations unless otherwise noted. The Biolux® Gaussia 
Luciferase assay kit used for the determination of gene suppression was purchased from 
New England Biolabs, Inc. Gibco® RPMI 1640 cell culture media (with and without folic 
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acid) were purchased from Life Technologies Corporation. KB cells (human epidermal 
cancer cells) expressing the Gaussia Luciferase gene (KB-GLuc) were prepared as 
previously reported. For reactions requiring nitrogen, ultrahigh purity nitrogen (purity ≥ 
99.998%) was used. Spectra/Por® regenerated cellulose dialysis membranes (Spectrum 
Laboratories, Inc) with a molecular weight cut-off of 12–14 kDa were used for dialysis. 
Polymer Synthesis 
Synthesis of γ-Benzyl-L-Glutamate-NCA  
 
γ-Benzyl-L-glutamate (10 g, 42.1 mmol) was added to a flame-dried reaction 
flask equipped with a stir bar and placed onto a Schlenk line; the flask was evacuated 
under reduced pressure followed by the introduction of  nitrogen. Approximately 100 mL 
of THF was added to yield a final concentration of ~0.1 g/mL, and the slurry was stirred 
under nitrogen for 20 min at 75 
o
C.  Triphosgene (6 g, 20.2 mmol) dissolved in 10 mL of 
THF was added to the mixture under a nitrogen atmosphere, and a drying tube was 
attached to the reaction flask.  The reaction was allowed to proceed for ~ 1 h, as THF 
slowly evaporated to give a final volume of ~ 20–30 mL.  After cooling, the mixture was 
precipitated into hexanes.  The recovered precipitate was then re-dissolved in THF; 2–3 g 
of decolorizing charcoal was then added and the mixture was allowed to stir overnight to 
remove residual hydrochloric acid.  The mixture was then passed through a Celite column 
to remove charcoal and re-precipitated into hexanes and cooled overnight.  The resulting 
white powder was collected and dried under vacuum overnight to produce γ-Benzyl-L-
glutamate-NCA, with standard yields between 75 and 85 %: 
1
H NMR (DMSO-d6) δ 
9.15–9.05 (Ring, COOH-NH, s), 7.40–7.25 (Ar, s), 5.15–5.05 (Ring, COOH-CH-CH2, t) 
2.60–2.40 (COOH-CH2, d) 2.2–1.80 (COOH-CH2-CH2, m).  
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Figure 17. Structures of poly(HPMA) (P1) and poly(HPMA)-NH2 macroinitiator (P2). 
 
 
MacroCTA of poly(HPMA) (P1) 
 
A poly(HPMA) macroCTA (P1) was prepared employing V-501 as the primary 
radical source and CEP as the chain transfer agent at 70 °C. To a 50 mL round-bottomed 
flask HPMA (2.86 g, 0.02 mol) dissolved in acetate buffer (pH 5.2, 0.27 M acetic acid 
and 0.73 M sodium acetate) was added and diluted to a final volume of 20 mL ([M]o = 1 
M). The round-bottomed flask was septum-sealed and purged with nitrogen for 1 h prior 
to polymerization. The macroCTA was reacted at a [M]o/[CTA] ratio = 400/1, while the 
[CTA]/[I] ratio was kept at 5/1, and the polymerization was allowed to proceed for 3.5 h 
before being quenched with liquid nitrogen followed by exposure to air. P1 was isolated 
by dialysis (pH 3–4) at 4 °C and recovered by lyophilization yielding 1.6 g (93%). 
Poly(HPMA) End-Capping with APMA (P2) 
 P1 was converted into a macroinitiator (P2) via simultaneous aminolysis and 
thiol-ene Michael addition with APMA. The reaction is as follows. P1 (305 mg, 9.5 
μmol) was combined with APMA (170 mg, 0.95 mmol) in a septum sealed scintillation 
vial equipped with a stir bar, then dissolved in 5 mL of DI H2O, and the pH elevated to 10 
with 0.1 M NaOH. The reaction temperature was maintained at 70 °C for 48 h. P2 was 
isolated by dialysis in DI H2O for 48 h and recovered by lyophilization yielding 300 mg 
(98%). 
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Figure 18. Structures of poly[HPMA-block-(γ-benzyl-L-glutamate)] (P3–P5) and 
poly[HPMA-block-(L-Glu)] (P6–P8) block copolymers. 
 
 
Poly(HPMA) Chain-Extension with γ-Benzyl-L-Glutamate-NCA (P3–P5) 
Poly(HPMA)-NH2 (P2) was used to initiate ring opening polymerization (ROP) of 
the γ-Benzyl-L-glutamate-NCA, thereby yielding polypHPMA-block-(benzyl-L-
glutamate)] block copolymers. A typical reaction is as follows.  In a 25 mL round-
bottomed flask, P2 (50 mg, 1.56 μmol) was dissolved in 5 mL of dry DMF. γ-Benzyl-L-
glutamate-NCA (10.3 mg, 38.9 μmol) was also dissolved in 5 mL of dry DMF and was 
immediately added via a glass, gas-tight syringe to the macroinitiator solution. Reactions 
were carried out for 5 days at 0 °C under a nitrogen atmosphere.
208
  The polymer was 
precipitated into ether, re-dissolved in chloroform, and re-precipitated into ether to 
eliminate unreacted NCA.   
Deprotection of Poly[HPMA-block-( γ -Benzyl-L-Glutamate)]Block Copolymers (P6–P8) 
Benzyl protecting groups were removed by hydrolysis in a 50:50 mixture of 
trifluoroacetic acid (TFA) and hydrobromic acid (HBr)
208
 at room temperature, followed 
by dialysis and lyophilizaton to yield pH-responsive P6–P8 block copolymers. Recovered 
yields were ~ 95 %. 
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Synthesis of poly(HPMA-stat-APMA) macroCTA (P9) 
A poly(HPMA-stat-APMA) macroCTA (P9) (CTA) was prepared employing V-
501 as the primary radical source and CTP as the chain transfer agent at 70 °C. HPMA 
(6.80 g, 47.5 mmol) and APMA (405 mg, 2.28 mmol) were added to a 100 mL round-
bottomed flask, dissolved in 1 M acetate buffer (pH 5.2, 0.27 M acetic acid and 0.73 M 
sodium acetate), and diluted to a final volume of 50 mL ([M]o = 1M). The initial feed 
composition was 95 mol % HPMA and 5 mol % APMA. The round-bottomed flask was 
septum-sealed and purged with nitrogen for 1 h prior to polymerization. The HPMA-stat-
APMA macroCTA was prepared with a [M]o/[CTA] ratio = 800/1, while the [CTA]/[I] 
ratio was kept at 5/1; the reaction was allowed to proceed for 3.5 h. The polymerization 
was quenched by rapid cooling in liquid nitrogen followed by exposure to air.  P9 was 
isolated by dialysis (pH 3–4) at 4 °C and recovered by lyophilization with a yield of 93%. 
 
 
 
 
Figure 19. Structures of poly(HPMA-stat-APMA) macroCTA (P9) and poly[(HPMA-
stat-APMA)-block-DMAPMA] (P10–P12) block copolymers. 
 
 
Synthesis of poly[(HPMA-stat-APMA)-block-DMAPMA] copolymers (P10–P12) 
P9 was chain extended with DMAPMA also using V-501 as the radical source at 
70 °C. DMAPMA and P9 were added to a round-bottomed flask, dissolved in acetate 
buffer to give [M]o = 1M. The round-bottomed flask was septum-sealed and 
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subsequently purged with nitrogen for 1 h. Block copolymers were prepared with a 
[M]o/[CTA] = 200, while the [CTA]/[I] was kept at 5/1. Each polymerization was 
terminated at predetermined time intervals by rapid cooling in liquid nitrogen and 
subsequent exposure to air. The poly[(HPMA-stat-APMA)-block-DMAPMA] 
copolymers were purified by dialysis (pH 3–4, 4°C) and recovered by lyophilization with 
yields of 92–97%. 
 Thiocarbonylthio moieties from poly[(HPMA-stat-APMA)-block-DMAPMA] 
copolymers were removed following a standard literature procedure.
209
 A typical reaction 
is as follows: P10 (500 mg,11.8 μmol) was added to a 25 mL round-bottomed flask and 
dissolved with 6.0 mL of DMF. Azobisisobutyronitrile (AIBN; 49.1 mg, 0.300 mmol) 
was then added to the flask giving an AIBN/copolymer ratio of 25:1. The following 
solution was then septum-sealed and purged with nitrogen for 1 h and allowed to react at 
70 °C for 4 h. The resulting copolymer was precipitated from DMF in cold, anhydrous 
diethyl ether and washed repeatedly. This step was repeated three times, and the 
copolymer was dried in vacuo overnight. The recovered yields were 85–89%. 
 
 
Figure 20. Structures of poly(HPMA-stat-APMA) macroCTA (P13) and poly[(HPMA-
stat-APMA)-block-DMAPMA] (P14–P16) block copolymers. 
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Copolymer functionalization with folic acid 
DiNHS-FA was prepared following a standard literature procedure.
42
 Following 
isolation of the chain terminated block copolymer, the pendent, functional, primary amine 
groups from the incorporated APMA were labeled with NHS-activated folic acid. A 
typical reaction is as follows: 50 mg (1.18 μmol) of P10 copolymer was dissolved in 390 
μL of DMSO to give a final concentration of 3.00 mM. A total of 150 times excess of 
diNHS-FA (116 mg) was then dissolved in 350 μL of DMSO, and the P10 copolymer 
solution was added to the diNHS-FA solution at a rate of 20 μL every 20 min. 
Triethylamine (TEA) was added to a final concentration of 39 mM to serve as a catalyst.  
The resulting solution was shielded from light and allowed to react for 48 h at room 
temperature. Following reaction, excess ammonium hydroxide (100% by volume) was 
added to quench the remaining activated esters from activated folic acid. Quenching was 
carried out for 24 h. The resulting reaction mixture was then directly placed in dialysis 
tubing and was first dialyzed against 0.6 M NaCl solution for 24 h followed by dialysis 
against DI water for 3 days. The folate-conjugated P10–P12 copolymers were recovered 
by lyophilization with yields of 96–98%. 
Formation of Hydrophilic-block-Cationic/Oligonucleotide Complexes 
Preparation of copolymer/GLuc DNA complexes for solution differential scanning 
calorimetry 
Folic acid labeled hydrophilic-block-cationic copolymers (P10–P12)/GLuc DNA 
complexes were prepared with a N:P ratio = 1 (i.e., neutral complexes). The GLuc DNA 
duplex concentration was maintained at 75 μM for all complexes. A typical preparation is 
as follows: 128 μL of a 600 μM GLuc DNA stock solution was combined with 417.7 μL 
of sodium cacadylate buffer (10 mM NaAs). Next, 454.3 μL of a 370.4 μM P10 stock 
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solution was added. The GLuc DNA/copolymer complex solution was vortexed and 
equilibrated for 30 min. After equilibration, the solution was degassed for 30 min prior to 
DSC measurements. The DNA and polymer stock solutions were prepared in 10 mM 
sodium cacadylate buffer at pH 7.2. 
Preparation of copolymer/siRNA complexes for gene suppression 
Folic acid labeled hydrophilic-block-cationic copolymers (P10–P12) /siRNA 
complexes were prepared with a N:P ratio = 1; the siRNA concentration was maintained 
at 100 nM. A typical preparation is as follows: 1.298 μL of a 185.2 μM P10 solution was 
combined with 3.3 μL of a 20 μM siRNA stock solution. This copolymer/siRNA complex 
solution was then diluted with 127.4 μL of RPMI 1640 medium containing no FBS. The 
solution was mixed by vortexing and equilibrated for 30 min. After equilibrating, the 
solution was further diluted with 528 μL of RPMI 1640 medium (supplemented with 
FBS) and vortexed to ensure a homogenous solution. The RNA and polymer stock 
solutions were prepared in 10 mM phosphate buffer at pH 7.4.  
Fluorescein-POPC (fPOPC) Liposome Preparation and Dye Release Studies 
The preparation of dye loaded POPC liposomes followed a standard literature 
procedure.
210
 In a 25 mL round-bottomed flask, 5 mg of POPC was dissolved in 10 mL of 
chloroform. Then the chloroform was removed by rotary evaporation, and subsequently, 
the flask was placed under a high vac for 8 h.  The resulting film was hydrated with PBS 
at the appropriate pH containing fluorescein (40 mM). The film was subjected to five 
freeze-pump-thaw cycles, and subsequently extruded (20 passes) through two stacked 
200 nm pore PC membranes at 40 °C. Finally, free fluorescein was removed via a 
Sephadex-25 column eluted with PBS (20 mM Pi, 150 mM NaCl) at the appropriate pH. 
The resulting fPOPC liposomes possessed hydrodynamic radii of 90 nm with PDIs < 0.2. 
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P6–P8 Block copolymers (200 μg/mL) were incubated with fPOPC at the appropriate pH 
for 1 h at room temperature. The mixture was then vortexed, and the fluorescence 
intensities measured using a PTI spectrofluorometer.  Measurements were acquired with a 
460 nm excitation (isobestic point) and 520 nm emission. The slit widths were adjusted 
for each pH and ranged from 0.5 mm–0.3 mm (pHs 4.0–7.4). All fluorescein dye release 
experiments were performed in triplicate with Triton-X100 (0.1 wt%) utilized as the 
positive control, and the percent release was determined using equation 1, in which F(T)  
is the fluorescence observed when incubated with Triton-X100, F(P) is the fluorescence 
observed when incubated with P6–P8 copolymers, and F(C) is the fluorescence observed 
with nothing added to the prepared POPC lipids. 
% Release = [F(T) - F(P)]/[F(T)-F(C)] * 100 (eq 1) 
Red Blood Cell Hemolysis Assay 
Bovine Blood was drawn into vacutainers containing EDTA. The blood was 
centrifuged, plasma decanted, and washed with 150 mM NaCl (three times). Finally, the 
red blood cells (RBC) were resuspended in PBS (10 mM Pi, 150 mM NaCl) at either pH 
7.4 or pH 5.5 to mimic physiological and endosomal pHs, respectively. Varying 
concentrations (10 μg/mL–400 μg/mL) of P6–P8 copolymers (100 μL) were incubated 
with 100 μL of RBC for 1 h at 37 °C. After incubation, the solution was centrifuged, and 
the supernatant was monitored at 541 nm for the presence of hemoglobin. All hemolysis 
experiments were performed in triplicate. Triton-X100 (0.1 wt%) was utilized as the 
positive control, and the percent release was determined using equation 2, in which A(T)  
is the absorbance observed when the liposomes are incubated with Triton-X100, A(P) is 
the absorbance observed when incubated with P6–P8 copolymers, and A(C) is the 
absorbance observed with nothing added to the red blood cells.  
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     (eq 2) 
Gene Suppression of Gaussia Luciferase in KB Cells 
Cell culture 
KB-GLuc cells were maintained and proliferated in RPMI 1640 (with folic acid) 
medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 
100 μg/mL streptomycin at 37 °C in 95% air humidified atmosphere and 5% CO2. 
Gene suppression 
Twenty four hours prior to treatment, the KB-GLuc cell medium was replaced 
with RPMI 1640 medium containing no folic acid and was supplemented with 10% FBS. 
Then the cells (12,000 cells per well) were seeded in a 48 well plate (Corning Inc.). Cells 
were treated with 200 μL of a hydrophilic-block-cationic copolymer (P10–P12)/siRNA 
complex solution. Dharmafect was utilized as the positive control, and the preparation of 
Dharmafect/siRNA complexes followed the manufacturer protocols. The delivered 
siRNA concentration was maintained at 100 nM for all complexes, and the KB-GLuc 
cells were treated for 24–48 h prior to measurement. The extent of Gaussia Luciferase 
suppression was determined using a Biolux® Gaussia Luciferase assay kit (New England 
Biolabs, Inc.). After incubation, 10 μL of medium was transferred to a 96 well plate and 
combined with 10 μL of assay buffer.  The luminescence was immediately determined 
utilizing a Biotek Synergy2 MultiMode Microplate Reader. All gene suppression studies 
were performed in triplicate. The passage number for KB-GLuc cells was 11. 
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Characterization 
Determination of (Co)Polymer Molecular Weight via Aqueous Size Exclusion 
Chromatography 
Poly(HPMA) (P1), Poly(HPMA)-NH2 (P2), and Poly[HPMA-block-(L-Glu)]s 
(P6–P8) were characterized by aqueous size exclusion chromatography (ASEC) using an 
eluent of 20 wt% acetonitrile/0.05 M Na2SO4 (aq) at a flow rate of 0.300 mL/min at 25 
°C, TOSOH Bioscience, LLC TSKgel columns (4 and 6 μm), a Polymer Laboratories 
LC1200 UV/Vis detector, a Wyatt Optilab DSP interferometric refractometer (λ = 690 
nm), and a Wyatt DAWN-DSP multi-angle laser light scattering (MALLS) detector (λ = 
633 nm). Absolute molecular weights and polydispersities were calculated using the 
Wyatt Astra (version 4) software. The dn/dc measurements were performed with a Wyatt 
Optilab DSP interferometric refractometer (λ = 690 nm) at 35 °C and determined using 
Wyatt DNDC (version 5.90.03). Conversions for the P1 and the chain extension with γ-
Benzyl-L-glutamate-NCA were determined by comparing the area of the monomeric UV 
signal detected at 274 nm at t0 to the area at tx using a Polymer Laboratories LC1200 
UV/vis detector.  
 Poly(HPMA-stat-APMA) (P9) and Poly[(HPMA-stat-APMA)-block-DMAPMA] 
(P10–P12) copolymers were characterized by aqueous size exclusion chromatography 
(ASEC) using an eluent of 1 wt% acetic acid/0.1 M Na2SO4 (aq) at a flow rate of 0.250 
mL/min at 25 °C, Eprogen, Inc. CATSEC columns (100, 300, and 1000 Å), a Polymer 
Laboratories LC1200 UV/Vis detector, a Wyatt Optilab DSP interferometric 
refractometer (λ = 690 nm), and a Wyatt DAWN-DSP multi-angle laser light scattering 
(MALLS) detector (λ = 633 nm). Absolute molecular weights and polydispersities were 
calculated using the Wyatt Astra (version 4) software. The dn/dc measurements for P9 
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and P10–P12 (co)polymers were performed with a Wyatt Optilab DSP interferometric 
refractometer (λ = 690 nm) at 35 °C and determined using Wyatt DNDC (version 
5.90.03). Conversions for P9 and the chain extension with DMAPMA were determined 
by comparing the area of the monomeric UV signal detected at 274 nm at t0 to the area at 
tx using a Polymer Laboratories LC1200 UV/vis detector.  
Determination of (Co)Polymer Compositions via 
1
H NMR 
P3–P8 block copolymer compositions before deprotection were determined with a 
Varian Mercury
PLUS
 300 MHz spectrometer in DMSO-d6 supplemented with 15 wt % 
TFA, and spectra were recorded with a delay time of 2 s. 
1
H NMR was used to determine 
the copolymer composition of P3–P5 copolymers by integration of the relative intensities 
of the methyne-proton resonances of HPMA at 3.75 ppm and the aromatic-proton 
resonances of γ-benzyl L-glutamate at 7.2 ppm.  
 Hydrophilic-block-cationic copolymer (P10–P12) compositions were determined 
with a Varian Mercury
PLUS
 300 MHz spectrometer in D2O, and spectra were recorded 
with a delay time of 2 s. 
1
H NMR was used to determine the copolymer composition of 
P9 and P10–P12 (co)polymers by integration of the relative intensities of the methyne-
proton resonances of HPMA at 3.75 ppm and the dimethyl-proton resonances of 
DMAPMA at 2.75 ppm. 
 Conjugation of folic acid to P10–P12 copolymers was verified by 1H NMR and 
UV/vis spectroscopy. 
1
H NMR was performed on a Varian Mercury
PLUS
 300 MHz 
spectrometer in DMSO-d6 with delay times of 2s. The amount of conjugated folic acid 
was estimated by integration of the methyne-proton resonance of HPMA at 3.75 ppm and 
the proton resonance of folic acid at 8.64 ppm (s, PtC7H, 1H). These values were 
estimated by employing a Lorentzian/Guassian line fit using MestReNova (version 6.0.2-
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5475). UV/vis spectroscopy was carried out using a PerkinElmer Lambda 35 
spectrophotometer for folic acid conjugated P10–P12 copolymers. An average extinction 
coefficient of 8000 M
-1
cm
-1
 for free folic acid in phosphate buffer (10 mM Pi, 100mM 
NaCl, pH 7.4) was used to determine the number of folic acid units. 
Determination of Hydrodynamic Radius for  (Co)Polymers and (Co)Polymer-
Oligonucleotide complexes  
Variable-angle dynamic light scattering (DLS) measurements of hydrophilic-
block-cationic copolymer/siRNA complexes under aqueous conditions were performed 
using incident light of 633 nm from a Spectra Physics Model 127 He-Ne laser operating 
at 40 mW. The angular dependence (60°–120° in 10° increments) of the autocorrelator 
functions was determined with a Brookhaven Instruments BI-200SM goniometer with an 
avalanche photodiode detector and TurboCorr correlator. DLS measurements were 
carried out at a complex concentration (siRNA + FA-block copolymer) of 1.0 mg/mL in 
phosphate buffer (10 mM Pi, pH 7.4) at 25 °C. The mutual diffusion coefficients (Dm) 
were determined from the relation 
 
in which Γ and q2 represent the decay rate of the autocorrelation function and the square 
of the scalar magnitude of the scattering vector, respectively. The hydrodynamic radius 
(Rh) was then calculated from the Stokes-Einstein equation 
 
in which η is the solution viscosity, kb is Boltzman’s constant, and T is the temperature in 
Kelvin. Zeta-potential measurements were carried out at a complex concentration of 0.5 
mg/mL in 20 mM NaCl solution at pH 7.4 using a Malvern Zetasizer Nano Series 
49 
 
 
Instrument. Samples were vortexed to ensure a homogeneous solution and equilibrated 
for 30 min at 25 °C prior to measurement. To remove dust, samples were centrifuged at 
14,000 RPM for 10 min. Both DLS and zeta-potential measurements were performed in 
triplicate. 
Circular Dichroism of poly[HPMA-b-(L-Glu)]s (P6–P8)  
The ellipticity of P6–P8 copolymers was determined utilizing a Jasco J-815 
circular dichroism spectropolarimeter. Samples were dissolved in DI H2O, and the pH 
was adjusted with 0.1 M HCl. Final sample concentrations ranged from 0.3–0.5 mg/mL, 
and solutions were allowed to equilibrate for 1 day prior to measurement. The spectra 
were obtained with a scan rate of 10 nm/min, a 0.5 nm bandwidth, and a time constant of 
2 s. The signal-to-noise for all spectra was doubled by averaging four scans.  The 
formation of α-helices was determined by monitoring the presence of the characteristic 
double minima at 220 and 208 nm.
211
  
 The ellipticity of the oligonucleotides (siRNA and GLuc DNA) as well as the 
P10–P12/oligonucleotide complexes was determined utilizing a Jasco J-815 circular 
dichroism spectropolarimeter. Oligonucleotides were prepared in phosphate buffer (10 
mM Pi, pH 7.4) at a concentration of 1.0 μM. Oligonucleotide/P10–P12 copolymer 
complexes were also prepared in phosphate buffer but at a concentration of 0.5 μM. 
Spectra were recorded with a scan rate of 10 nm/min, a 0.5 nm bandwidth, and a time 
constant of 2 s. The signal-to-noise was doubled for all spectra by averaging four scans. 
To determine defects of the secondary structure, the characteristic peaks of B-form 
oligonucleotide (right-handed helices) at 280 nm (maximum), 250 nm (minimum), and 
260 nm crossover (from positive to negative) were monitored for discrepancies before 
and after complexation.
212
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Differential Scanning Calorimetry of Hydrophilic-block-Cationic Polymers and 
Hydrophilic-block-Cationic-Oligonucleotide Complexes 
All calorimetric experiments were carried out using a Calorimetric Sciences 
Corporation Nano DSC-II solution differential scanning calorimeter (DSC). Sodium 
cacadylate buffer (10 mM, pH 7.2) was used for the running buffer. The GLuc DNA 
(analogue of Gaussia Luciferase siRNA) concentration was maintained at 75 μM while 
the concentrations of hydrophilic-block-cationic (P10–P12) copolymers were adjusted to 
maintain a nitrogen-to-phosphate (N:P) ratio equal to 1 (i.e., neutral complexes). CpCalc 
(Version 2.1, Calorimetric Sciences Corp.) was used to subtract buffer-buffer scans from 
buffer-sample scans. Linear-polynomial baselines were applied to each scan for the 
determination of the molar heat capacity. 
Determination of Copolymer-Oligonucleotide Complex Binding Strength Utilizing 
Analytical Ultracentrifugation 
Sedimentation-velocity experiments were performed in a Beckman XLA 
Analytical Ultracentrifuge at 20 °C at 50K rpm. Data were collected at 260 nm and 
processed in DCDT+ to produce g(s) sedimentation coefficient distributions.
213
 A fixed 
concentration of ssDNA was titrated with increasing concentrations of P10 or P11. Data 
were converted to Sw and analyzed to a 1:1 binding model in Scientist 3.
214
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CHAPTER IV 
 
RESULTS AND DISCUSSION 
 
Section I. Endolytic, pH-Responsive HPMA-b-(L-Glu) Copolymers Synthesized via 
Sequential Aqueous RAFT and Ring Opening Polymerizations 
Overview 
 Remarkable progress has been made over the last decade in the design of 
polymeric vehicles in order to achieve cellular targeting,
215
 increased blood 
circulation,
216–218
 drug/gene protection,
219–221
 reduced  cytotoxicity,
222–225
  etc.
20
 Despite 
these advances, a number of challenges remain for efficacious gene/drug delivery.
226,227
  
An ideal carrier should provide protection and solubility during circulation as well as a 
mechanism for targeting and entry into specified cells. Once delivered the 
drug/gene/carrier complex must overcome other critical barriers including trafficking to 
the lysosome, where the cargo can be degraded, or transport outside the cell into the 
extracellular milieu. A promising approach for an ideal polymeric drug vehicle is 
inclusion of a modular segment promoting disruption of the endosomal membrane at an 
appropriate time, allowing drug/gene release into the cytoplasm. 
 Some polymeric carriers rely on an osmotic swelling mechanism (“proton-sponge 
effect”) to escape the endosome.  Alternatively, poly(amido amines), prepared by 
Duncan
228–230
  and Wagner,
231
  and poly(aspartamides), prepared by Kataoka and 
coworkers,
232–234
 exploit the enhanced buffering capacity of pendant and backbone 
amines to facilitate endosomal swelling and rupture. While these systems demonstrate 
improved efficacy both in vitro and in vivo, the toxicity of amines is still a concern as is 
the necessity of a “charge-shielding” block such as PEG or HPMA.  In order to alleviate 
unwanted electrostatic effects and undesirable toxicity, Convertine et al.
38,39,235
 prepared 
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endosomolytic block copolymers containing N,N-(2-dimethylaminoethyl)methacrylate 
(DMAEMA), propylacrylic acid, and butyl methacrylate (BMA). DMAEMA served to 
bind siRNA, while propylacrylic acid masked the hydrophobic BMA. At endosomal pH, 
propylacrylic acid segments are protonated, thus increasing the hydrophobicity of the 
block copolymer and destabilizing the endosomal membrane. 
 Naturally-occurring peptides and proteins provide several pathways for 
endosomal disruption via hydrophobic alignment between the α-helix and bilayer surface, 
usually resulting in electrostatic interactions of the membrane that  promote 
permeability.
236
 Such pH-responsive coil-to-helix transitions are attractive features of 
these biopolymers that offer opportunities for synthetic mimicry. Peptides based on 
melittin,
237
 a component of bee venoms, as well as the lytic amino-terminus of the 
influenza virus HA-2
238
 have been conjugated to polymeric vehicles increasing pDNA 
and siRNA efficacy both in vitro and in vivo. To realize a nature-inspired mimic, N-
carboxyanhydride (NCA) polymerization
239–241
 has been used to prepare synthetic 
peptides that undergo stimuli-responsive conformational changes into α-helices, β-sheets, 
and other ordered structures.
242
 These conformational changes are facile and reversible, 
and they have been capitalized on for triggered drug release in vitro.
243
  
 In recent years our research has centered on the development of a modular 
drug/siRNA delivery platform, capitalizing on the attributes afforded by aqueous RAFT 
polymerization
7
 for synthesis of biologically relevant systems.
40,41
 (For example, homo- 
and block copolymers of (3-guanidinopropyl)methacrylamide (GPMA) were shown to 
serve efficiently as cell-penetrating mimics of natural peptides.
244
 Folate targeting groups 
for receptor-mediated endocytosis have also been attached to both interpolyelectrolyte 
siRNA complexes
42
 and amphiphilic diblock copolymers with disulfide-bound, pendant 
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siRNA.
245
 While siRNA uptake and trafficking to the endosome occurred with both of 
these charge-neutral delivery vectors, only the former showed significant gene 
knockdown. We attribute negligible gene suppression to inability of the latter construct as 
designed to escape the endosome. Herein, we report the controlled synthesis, 
characterization, and endolytic activity of a series of HPMA-block-(L-Glu) copolymers 
specifically designed to elicit membrane disruption. To our knowledge, this facile 
synthetic approach using sequential RAFT polymerization and aminolysis to produce a 
telechelic, amine-functional macroinitiator followed by NCA polymerization and 
hydrolysis has not been previously reported. The pH-dependent coil-to-helix transitions 
of the L-glutamic acid (L-Glu) block were followed by circular dichroism. Membrane 
disruption was demonstrated by red blood cell hemolysis and fluorescein release from 
POPC vesicles.  
 
 
 
 
Scheme 1. Synthetic pathway for the preparation of P6–P8 copolymers. 
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Synthesis of HPMA Homopolymer and Chain-end Functionalization 
 P1 was prepared via aqueous RAFT polymerization (Scheme 1) in order to yield a 
water-soluble, biocompatible segment with telechelic
246,247
 functionality appropriate for 
further modification to a macroinitiator for block copolymerization.  The polymerization 
was carried out in acetate buffer (pH 5.2) at 70 °C using 4-cyano-4-
[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CEP) and 4,4’-azobis(4-
cyanopentanoic acid) (V-501) as the CTA and initiator, respectively. P1 was end-capped 
with a primary amine containing monomer N-(3-aminopropyl)methacrylamide (APMA) 
via simultaneous aminolysis and thiol-ene Michael addition. To ensure quantitative thiol-
ene coupling, the pH was elevated (>10) to deprotonate the amine, and the reaction was 
allowed to proceed at elevated temperature (70 °C) for an extended period of time (48 h). 
End-capping efficiency was determined via a Ninhydrin assay
248
 (See Appendix), and 
primary amine incorporation exceeded 96%. Aqueous size exclusion chromatography 
(ASEC) was used to determine PDIs, molecular weights, and macro disulfide coupling; 
the ASEC chromatograms (Figure 20) are shown prior to and after chain-end 
functionalization with APMA, indicating narrow distributions (PDIs <1.1). 
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Figure 21. ASEC-MALLS of P1 (black) and P2 (red). P2 is offset for clarity. 
 
 
 
 
 
Figure 22.  
1
H NMR of P2 and P3–P5. P2 was recorded in D2O while P3–P5 were 
recorded in DMSO-d6 supplemented with TFA (15 wt%). 
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Synthesis of (HPMA-b-Glu) Block Copolymers  
 
Utilizing P2 as a macroinitiator, a series of chain extensions was accomplished 
via ring opening polymerization of N-carboxyanhydride, γ-Benzyl-L-glutamte-NCA, in 
DMF. By altering the [M]/[I] ratio, where [M] = γ-Benzyl-L-glutamte-NCA (benzyl 
protected glutamic acid) and [I] = P(HPMA)-NH2, a range of block lengths was targeted. 
In order to prevent anticipated side reactions,
239,249–252
 the polymerizations were 
conducted at 0 °C under an atmosphere of nitrogen. Copolymer compositions for the 
block copolymers were determined using 
1
H NMR by comparing the relative intensities 
of the aromatic-protons resonances of benzyl L-glutamate units at 7.2 ppm to the 
methyne-proton resonances of the HPMA repeats at 3.75 ppm. Spectra of the 
poly(HPMA220)-NH2 macroinitiator (P2) and three copolymers with benzyl-L-glutamate 
blocks of DP 33, 58, and 78 are shown in Figure 21. Deprotection of benzyl-L-glutamate 
units was accomplished under acidic conditions at room temperature using a 50:50 
mixture of TFA and HBr.
208,253
 Copolymer molecular weights, PDIs, compositions, and 
dn/dc values are presented in Table 1.  Size exclusion chromatograms (Figure 22) 
indicate successful chain extension with shifts to lower elution volume as the 
polymerization progressed. The copolymer molecular weights determined directly by 
ASEC-MALLS correlate well with those calculated from NMR compositional data; PDI 
values are narrow, ranging from 1.08–1.20. The deviations in experimental and 
theoretical Mn values are relatively small and may be attributed to incomplete conversion 
of the HPMA macroCTA to the amine-terminated macroinitiator upon addition of 
APMA.  
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Figure 23.  ASEC-MALLS of P1 (black), P6(red), P7 (blue), and P8 (cyan). 
 
α-Helix Formation  
 
Circular dichroism
211
 is an exceptionally valuable technique for ascertaining 
structural information of proteins,
254
 nucleic acids,
255
 and chiral self-assemblies.
256
 By 
measuring the differences between left-handed and right-handed absorbances of chiral or 
asymmetric species, insight into the secondary structure can be gained. The utility of the 
P6–P8 copolymers according to our synthetic design lies in the pH-responsive L-
glutamic acid block which upon protonation is expected to self-assemble into an α-helix. 
Ultimately, these α-helices should mimic those discussed in the introduction and disrupt 
the integrity of lipid membranes. Figure 23 illustrates the pH-dependence of the coil-to-
helix transition for each block copolymer as well as for P1. Not surprisingly, P1 alone 
shows no evidence of α-helix structure. However, as the pH is reduced, the CD spectra 
indicate pronounced development of α-helices for both P7 (Figure 23-C) and P8 (Figure 
23-D); however, P6 with the lowest glutamic acid block length (Figure 23-B) exhibits a 
spectrum lacking discernible evidence of helix formation. As the pH is further lowered, 
the characteristic signal of the copolymers with longer helical L-Glu blocks becomes 
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even more pronounced; eventually, the signal is lost at pH values below 4.5 due to 
precipitation and/or onset of flocculation.  
 
 
 
Figure 24.  MRE as a function of pH for (A) P1, (B) P6, (C) P7, and (D) P8. 
 
 
Fluorescein Release from POPC Lipid Membranes and Red Blood Cell Hemolysis 
 
Leakage of fluorescent dyes from artificially prepared liposomes is a commonly 
used assay to elucidate membrane-particle interactions, and it is widely employed in the 
study of antimicrobial peptides/polymers.
257–260
 This technique is well suited for studying 
membrane disruption at endosomal conditions. By varying the pH, the endolytic activity 
with respect to α-helical content was investigated using fluorescein loaded 2-oleoyl-1-
palmitoyl-sn-glycero-3-phosphocholine (POPC) lipids (fPOPC). P6–P8 (200 µg/mL) 
copolymers were incubated with fPOPC liposomes for 1 h prior to measurement. Figure 
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24 shows the extent of fluorescein release from liposomes as a function of pH P6–P8 
copolymer as well as for the HPMA macroinitiator normalized to L-Glu content. No 
fluorescein release is observed until pH values are progressively lowered below 6. For P7 
and P8, maxima representing 80 % and 70 % release, respectively, occur at pH 5.0; Only 
~ 30 % release was observed for P6. These values are consistent with CD data. As the pH 
drops, L-glutamate units are converted to α-helix forming L-glutamic acid, and the extent 
of fPOPC membrane leakage is related to helical block content.  
 
  
 
Figure 25.  Fluorescein release from POPC liposomes as a function of pH. fPOPC 
liposomes were incubated 1 h with P6 (black), P7 (red), and P8 (cyan). Triton-X100 was 
utilized as the positive control. Error bars represent the standard deviation. 
 
 
 The endolytic characteristics of these stimuli-responsive copolymers were also 
investigated utilizing a red blood cell hemolysis assay at pH 5.5.  Figure 25 shows % 
hemolysis as a function of block copolymer concentration, normalized for L-Glu units.  
As expected P1 shows no hemolytic activity, while P7 and P8 show notable 
concentration-dependent release profiles, reaching values of nearly 90 % after 1 h of 
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incubation. On the other hand, P6 which has a much shorter block length displays 
substantially lower hemolysis across the concentration range.  These results seem to be in 
agreement with previous studies indicating a helical block length dependence on 
membrane destabilization.
236
  
 
Figure 26.  Percent hemolysis as a function of copolymer concentration at pH 5.5. Triton-
X100 was utilized as the positive control, and the error bars represent the standard 
deviation of triplicate experiments. 
 
 
Table 1 
Molecular weight (Mn, Mw), polydispersity (PDI), composition, conversion, and dn/dc 
values for P6–P8 copolymers. 
Sample 
Mn,Th
a
 
(kDa) 
Mn,exp
b
 
(kDa) 
Mw
b
 
(kDa) 
PDI
b
 
Comp 
(%)
c
 
% 
conv.
d
 
dn/dc
e
 
P2 30.6 32.1 34.5 1.08 100:0 53 0.170 
P6 34.8 37.8 44.6 1.18 87:13 96 0.145 
P7 39.1 42.1 50.5 1.20 79:21 98 0.145 
P8 42.8 45.6 53.4 1.17 65:25 94 0.144 
 
aTheoretical Mn, (Mn,Th), calculated from conversion (ρ) using Mn,Th = ([M]o/[CTA]) x Mw,monomer x ρ + Mw,CTA. 
bAs determined by 
aqueous SEC-MALLS. cAs determined by 1H NMR. dConversions were determined by comparison of the UV signal at 274 nm of the 
monomer at t0 to that at tx. 
eDetermined by Wyatt Optilab DSP interferometric refractometer (λ = 690 nm). 
61 
 
 
Section II. Block Ionomer Complexes Consisting of siRNA and Aqueous RAFT 
Synthesized Hydrophilic-block-Cationic Copolymers: Monitoring Complex Dissociation 
and the Effects on Gene Suppression 
Overview 
 
 The discovery of siRNA,
1
 the effector molecule in the RNA interference (RNAi) 
pathway in 1998, has resulted in extensive interventive therapy research giving the 
potential to regulate nearly any gene of interest.
261–263
 However, in vitro delivery of 
siRNA alone is limited because of enzymatic degradation and lack of cell specificity. As 
a result, numerous approaches to more efficient delivery have been investigated.
20,264,265
 
One promising approach capitalizes on the formation of interpolyelectrolyte complexes 
(IPECs) between the anionic groups along the phosphodiester backbone and a hydrophilic 
cationic polymer.
266,267
 These IPECs stabilize the RNA from nucleases;
41
 however, the 
molar ratio of cationic to phosphodiester repeating units should be ≈ 1. Nitrogen-to-
phosphate (N:P) values greater than one lead to non-specific transfection and those less 
than one to reduced cellular uptake. Recent advances in controlled polymerization 
techniques including RAFT,
2,33,268
 aRAFT,
35,48
 ATRP,
269
 and ROMP
270
 now allow the 
formation of well-defined cationic block copolymers in which block length and 
stoichiometry along the IPEC can be “tuned.” These complexes are often referred to as 
block ionomer complexes (BICs) and possess a balance of non-complexing hydrophilic 
segment(s) and binding segments. A potential advantage of BICs is the reduction of off-
target effects and toxicity.
271
  
 The formation of IPECs has been extensively studied and in general, three 
parameters constitute complex formation;
272,273
 hydrogen bonding, hydrophobic effects, 
and charge. Poly(ethylene glycol) (PEG) has been shown to form stable complexes with 
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proteins at low pH and up to pH 8, and such complexes are formed strictly through 
hydrogen bonding.
274,275
 Hydrophobic interactions are more difficult to ascertain, and the 
effects of hydrophobicity are generally manifested in a cooperative fashion.
276,277
 Xia et 
al. demonstrated enhanced binding to lysozyme by introducing a pyrene label to poly(2-
acrylamido methylpropylsulfate).
278
 The enhanced biding resulted from interactions 
between the probe and lysozyme’s hydrophobic cleft. Interestingly, molecular dynamics 
simulations have demonstrated oligonucleotide strand separation when complexed with 
weakly interacting charge associations in conjunction with hydrophobic moieties such as 
gold nanoparticles.
279
 IPECs based on charge are most common and are routinely 
employed for nucleotide delivery. IPECs prepared via electrostatic associations 
consistently maintain a 1:1 stoichiometry, and deviations from 1:1 binding result from 
drastic changes in architecture (e.g., branching). Furthermore, regardless of a strong or 
weak polyelectrolyte, polyion exchange and substitution readily occur when a small 
molecular salt is present.
280,281
 Ammonium-based polymers (e.g., PEI,
19,282
 DMAPMA,
40–
42
 DMAEMA
38,39,283
) are typically utilized for the cationic block, but polymers possessing 
phosphonium groups have also been reported.
284–288
 
 To promote efficacious delivery, polymeric vehicles incorporate multiple modes 
of interaction. Reineke and co-workers
289,290
 investigated IPEC formation between 
plasmid DNA (pDNA) and poly(glycoamidoamines) (PGAAs). It was determined that 
while long-range charge-charge interactions drive IPEC assembly, hydrogen bonding 
plays a vital role in stabilizing the complexes. Furthermore, the less dense amine-
containing polymers have stronger electrostatic associations with pDNA. 
 Our research group has focused on the development of controlled, tailored 
(co)polymers afforded via RAFT polymerization, and more specifically, the synthesis of 
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these constructs directly in aqueous media. Recent efforts have centered on a rational 
design for preparing polymeric drug/gene delivery systems, thus allowing construction of 
responsive micelles,
117,123,191
 theranostics,
40
 peptide mimics,
244
 modular copolymers,
291,292
 
and vehicles for endosomal escape.
293
 We have previously demonstrated targeted delivery 
of siRNA via BICs as well as with disulfide-bound amphiphilic copolymers.
42,70
 In our 
experience, we have noted a block-length dependence for efficacious siRNA delivery.
41
 
Although mechanisms for IPEC and BIC formation have been proposed, information 
regarding complex dissociation and the role of block length on IPEC stability is lacking. 
To our knowledge, this is the first study directed toward elucidating the nature of the 
cationic block length with regard to gene suppression utilizing well-defined block 
copolymers which form stable, monodisperse BICs with oligonucleotides. Herein, we 
report the synthesis of hydrophilic-block-cationic copolymers prepared by aRAFT, and 
through the use of a combination of circular dichroism (CD), analytical 
ultracentrifugation (AUC), and solution differential scanning calorimetry (DSC), 
structural and binding effects on gene suppression with regard to cationic block length 
(DMAPMA) were ascertained. Increasing DMAPMA length promotes complex stability 
and increases the binding constant. Due to large binding constants, the thermodynamics 
of BIC dissociation could not be determined; however, the kinetics of gene suppression 
are indicative of an ion exchange/substitution mechanism, providing evidence for a 
pathway for siRNA and/or oligonucleotide release in vitro. 
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Synthesis of poly(HPMA-stat-APMA) macroCTA, chain extensions with DMAPMA, and 
Folic acid conjugation 
 
 A statistical macroCTA consisting of a theoretical feed ratio of 95 mol% HPMA 
and 5 mol% APMA was prepared via aqueous RAFT polymerization (Scheme 2). The 
polymerization was performed in 1 M acetate buffer (0.27 M acetic acid, 0.73 M sodium  
acetate, pH = 5.2) at 70 °C using 4-cyanopentanoic acid dithiobenzoate (CTP) and 4,4’-
azobiscyanovaleric acid (V-501) as the CTA and initiator, respectively. Experimentally 
determined compositions for the macroCTA by 1H NMR closely resemble initial feed 
ratios which were calculated to be 93 mol% HPMA and 7 mol% APMA. 
 
 
Scheme 2. Synthetic pathway for the preparation of poly[(HPMA-stat-APMA)-block-
DMAPMA] copolymers and subsequent complexation with oligonucleotides. 
 
 
The resulting poly(HPMA171-stat-APMA13) (P9) macroCTA was subjected to a series of 
chain extensions with DMAPMA under similar conditions (Scheme 2). Figure 26 
illustrates ASEC-MALLS chromatograms for the macroCTA and these subsequent chain 
extensions indicating shifts to lower elution volume, narrow polydispersities (PDI) (< 
1.10), and unimodal peaks. Copolymer composition, copolymer molecular weights (Mn 
and Mw), PDI, and dn/dc values are presented in Table 2 for P9 and poly[(HPMA-stat-
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APMA)-block- DMAPMA] (P10–P12) copolymers. Copolymer compositions were 
determined via 
1
H NMR by integration of the relative intensities of the methyne-proton 
resonance of HPMA at 3.75 ppm to that of the dimethyl proton resonances of DMAPMA 
at 2.75 ppm in D2O. The compositions obtained from 
1
H NMR correlate well with 
molecular weights determined via ASEC-MALLS (Figure 25). 
 
Table 2  
Molecular weight (Mn, Mw), polydispersity (PDI), composition, conversion (ρ), and dn/dc 
values for P1 macroCTA and P2–P4 copolymers. 
Sample 
Mn,Th
a
 
(kDa) 
Mn,exp
b
 
(kDa) 
Mw
b
 
(kDa) 
PDI
b
 
Comp 
(%)
c
 
% 
conv.
d
 
dn/dc
e
 
P9 22.2 24.0 26.4 1.10 93:7 20 0.168 
P10 27.2 29.3 31.4 1.07 80:6:14 14 0.167 
P11 32.4 33.0 35.3 1.07 71:5:24 25 0.167 
P12 41.4 41.5 44.4 1.07 59:5:36 47 0.165 
 
 
 
 
 
Figure 27. ASEC-MALLS of poly(HPMA-stat-APMA) macroCTA (P9) and subsequent 
chain extensions with DMAPMA (P10–P12). 
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 The pendent, primary amine of APMA conveniently allows for facile conjugation 
of electrophilic compounds, and in our case, the cellular targeting moiety, folic acid 
(Scheme 2). Conjugation of folic acid was conducted in DMSO at room temperature for 
48 h. 
1
H NMR and UV/vis spectroscopy were used to quantify the folic acid conjugation 
for each hydrophilic-block-cationic copolymer (See Appendix), and the content exceeded 
92% (~12 out of 13 amines). We are most concerned with the delivery of neutral 
complexes (i.e., nitrogen-to-phosphate (N:P) ratio = 1) as excessive cationic charges (N:P 
> 1) would encourage universal transfection as well as increase cytotoxicity. With folic 
acid pendently conjugated to APMA, allowing for targeted cellular delivery, only the 
tertiary amine containing block of DMAPMA will form an electrostatic association with 
the chosen oligonucleotide, while the HPMA segments promote water stability, 
biocompatibility, and non-immunogenicity. We have chosen aRAFT as it allows for 
facile synthesis of tailored architectures with predetermined molecular weights and low 
PDIs under mild conditions. Our narrowly dispersed, well-defined, folic acid-conjugated 
hydrophilic-block-cationic copolymers are especially suited for formation of 
homogeneous block ionomer complexes (BIC) with oligonucleotides, therefore allowing 
for the correlation of BIC dissociation to the extent of gene suppression in vitro. 
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Figure 28. Gel electrophoresis of siRNA (Lane 1) and GLuc DNA (Lane 5) as well as 
oligonucleotide/copolymer complexes prepared with P2 (Lanes 2 and 6), P3 (Lanes 3 and 
7), and P4 (Lanes 4 and 8). 
 
Table 3  
 
The hydrodynamic radii (Rh), polydispersity (PDI), and ζ-potential for siRNA and GLuc 
DNA-hydrophilic-block-cationic copolymer complexes. 
Sample Rh (nm) PDI
a
 ζ-potential (mV) 
siRNA N/A* N/A* -35.1 
siRNA-P10 18.7 0.206 -2.16 
siRNA-P11 26.3 0.058 1.35 
siRNA-P12 31.7 0.046 2.38 
Gluc DNA N/A* N/A* -36.2 
DNA-P10 18.9 0.214 -2.36 
DNA-P11 26.8 0.064 -0.09 
DNA-P12 31.8 0.042 1.87 
 
 
Characterization of hydrophilic-block-cationic/oligonucleotide complexes 
 We chose to use a double-stranded DNA (dsDNA) which is analogous to siRNA 
(vide infra), so complexes formed with DNA should resemble those prepared with RNA 
for comparative purposes. Table 3 presents the hydrodynamic radius (Rh), ζ-potential, and 
PDI for GLuc/copolymer and siRNA/copolymer complexes. Not surprisingly, both GLuc 
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DNA and siRNA complexes increase in size (Rh) with increasing DMAPMA block length 
(18–30 nm); interestingly, these systems become more monodisperse with increasing size 
(PDIs < 0.2). Typically, intercomplex bridging is observed for larger cationic block 
lengths, and we have observed similar phenomena utilizing an analytical ultracentrifuge. 
Charge neutrality was confirmed by ζ- potential and gel electrophoresis (Figure 28). 
Lanes 2–4 and 6–8 (Figure 28) represent the BICs prepared with either siRNA or GLuc 
DNA, respectively; lanes 1 and 5 serve as the siRNA and GLuc DNA controls, 
respectively. As can be seen, both DNA and RNA condensation occur while maintaining 
charge neutrality, an important requirement which prevents off-target effects and 
cytotoxicity. The complexes prepared with GLuc DNA or siRNA are comparable, 
monodisperse, and charge-neutral. 
 Table 4  
The maximum, cross-over, and minimum for oligonucleotide and oligonucleotide-
hydrophilic-block-cationic copolymer complexes. 
Sample λMax (nm) λCross-over (nm) λMin (nm) 
siRNA 262 253 235 
siRNA-P10 263 253 234 
siRNA-P11 263 253 234 
siRNA-P12 266 251 233 
Gluc DNA 272 260 250 
DNA-P10 287 269 254 
DNA-P11 293 271 253 
DNA-P12 299 282 257 
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 Nucleic acids possess secondary structure alterations of which can be monitored 
via circular dichroism (CD).
294,295
 Typically, B-form (standard, right-handed helix) DNA 
possess three CD spectral characteristics: a 280 nm maximum, a 250 nm minimum, and a 
260 nm crossover (from positive to negative).
212
 However, these trends are sequence 
dependent. The CD spectrum for GLuc DNA is presented in Figure 29-A (black curve). 
Table 4 presents the minimum, maximum, and the crossover for GLuc DNA, siRNA, and 
oligonucleotide-hydrophilic-block-cationic copolymer complexes. The GLuc DNA 
possesses a 272 nm maximum, a 250 nm minimum, and a 260 nm crossover. These 
spectral characteristics drastically shift when complexed with hydrophilic-block-cationic 
copolymers, and when complexed with P10, P11, and P12 to form BICs with GLuc 
DNA, a red shift in the maximum, crossover, and minimum is observed. Additionally, a 
decrease in ellipticity for the maximum and a more negative increase in the ellipticity for 
the minimum are observed; these trends exist for all polymers utilized. These changes in 
structure are similar to the melt (thermal denaturation) spectra (See Appendix) of GLuc 
DNA. 
 
 
Figure 29. Molar ellipticity of (A) GLuc DNA and DNA-hydrophilic-block-cationic 
copolymer complexes, and (B) siRNA and siRNA-hydrophilic-block-cationic copolymer 
complexes.  
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 Alternatively, RNA helices typically exist in the A-form (also right-handed helix), 
which possesses a 270 nm maximum, 240 nm minimum, and a 250 nm crossover. Again, 
these characteristics are sequence dependent. Figure 29-B depicts the molar ellipticity of 
siRNA (Black curve) and siRNA/hydrophilic-block-cationic copolymer complexes (Red, 
Blue, and Green curves). The siRNA possesses a 262 nm maximum, a 235 nm minimum, 
and a 253 nm crossover. These characteristics remain when siRNA is complexed with 
P10, P11, and P12, except a decrease in ellipticity for the maximum and a more negative 
increase in ellipticity for the minimum are observed. The changes to siRNA’s spectral 
characteristics when bound to P10, P11, and P12 also resemble melting spectra (See 
Appendix). We hypothesize that, for both siRNA and GLuc DNA, complexation slightly 
denatures the helix to minimize charge repulsion thus stabilizing the block ionomer 
complex.  
 Binding characteristics of Hydrophilic-block-Cationic/GLuc DNA complexes as 
determined via analytical ultracentrifugation and solution differential scanning 
calorimetry 
 Analytical ultracentrifugation was conducted to determine characteristics of 
complex formation. Utilizing double-stranded DNA (dsDNA), samples were too 
polydisperse to accurately determine the binding parameters, therefore the single strands 
(sense strand and antisense strand) were utilized for AUC.  (Figure 30). P10 (Figure 30-
A) and P11 (Figure 30-B) were titrated into a fixed amount of ssDNA. From these 
titrations, complexation readily occurs as evidenced by shifts to increased apparent 
sedimentation (SApparent) values. Furthermore, an association constant may be obtained via 
a global fit to a 1:1 stoichiometric model.
214
 The binding constants related to complex 
formation utilizing P10 and P11 were in the range of 10
4
 and 10
7
, respectively, values 
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typical for electrostatic association. Although complexation was observed for P10 and 
P11, ssDNA titrated with P12 produced polydisperse complexes, and a binding constant 
was not determined.  
 
 
Figure 30. Monitoring the association of single-stranded DNA with hydrophilic-block-
cationic copolymers. g(s*) sedimentation coefficient distribution of a titration of ssDNA 
with P10 (A) and P11 (B). 
 
 
 DSC measurements of the excess heat capacity relative to a reference cell allow 
thermodynamic determinations of dissociation (folded-to-unfolded).
296
  From these 
melting profiles, complex stability can be elucidated. Due to the large amounts of 
material required for DSC, utilizing siRNA becomes cost prohibitive. Therefore, a 
dsDNA analogue of siRNA was used in all of our DSC studies.  
 Figure 31 depicts the molar heat capacity (MHC) thermograms, for GLuc DNA 
and GLuc DNA/copolymer complexes formed with P2, P3, and P4. The GLuc DNA 
duplex dissociation temperature, or melting temperature (Tm), was determined to be 54.4 
°C for uncomplexed dsDNA (Figure 31-A). Furthermore, Tm values increased with 
DMAPMA block length (P10, 88.4 °C, P11 90.2 °C, P12, 91.8 °C, respectively (Figures 
31 B-D). This trend of increasing Tm indicates that polymer complexation significantly 
stabilizes the DNA duplex, greater cationic block length conferring greater duplex 
stability. These findings are also corroborated by the changes in secondary structure as 
observed with CD (Figure 29).  
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Figure 31. Molar heat capacity thermograms for (A) GLuc DNA, (B) DNA-P10 
complexes, (C) DNA-P11 complexes, and (D) DNA-P12 complexes. 
  
 Since the magnitude of the melting endotherm, representing the breaking of 
hydrogen bonds between the sense and antisense strands, may mask changes 
corresponding to dissociation, ssDNA was separately complexed with hydrophilic-block-
cationic copolymers P10–P12. Figure 32 presents the excess heat capacity (ΔCp,XS) 
thermograms for copolymer complexes prepared with the sense and antisense strands. For 
the scanned temperature range (30 °C–125 °C), no dissociation is observed (i.e., no 
exotherm or endotherm) regardless of hydrophilic-block-cationic polymer utilized in 
complexation. The absence of dissociation is not surprising, since the binding constants 
are so large. A binding constant of 10
4
 would indicate 1/10000 dissociated molecules. 
With the concentration used, the dissociated species would be at or below the detection 
limit for the calorimeter.  
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Figure 32. Excess heat capacity thermograms of hydrophilic-block-cationic copolymer 
binding to GLuc antisense and sense strands. 
 
 
Gene down-regulation 
 To determine the role of cationic block length on gene suppression, gene down-
regulation was monitored in KB cells which stably express Gaussia Luciferase. Figure 33 
demonstrates the kinetics of gene knockdown as a function of DMAPMA block length. 
Increasing the cationic block slightly increases gene suppression as P12 exhibits ~10 % 
higher suppression than P10; however, increasing the cationic block also increases the 
cytotoxicity (see Appendix). Appreciable cell death occurred with P12 while P10 
maintained negligible cytotoxicity over a 48 h period. Interestingly, the observed gene 
knockdown maximum is shifted toward longer times when increasing DMAPMA block 
length, from 32 h for P10 to 40 h for P12. These shifts in the maxima agree with 
literature reports for polyion exchange/substitution rates, since increasing molecular 
weight increases the time required for complete ion exchange.
280,281,297
 Regardless of the 
nature of a dissociation or ion exchange/substitution mechanism, the trend is clear—an 
increase in binding/stability and the expected increase in time to reach maximum gene 
suppression. 
74 
 
 
 
Figure 33. Gene knockdown kinetics for complexes consisting of siRNA and P10 (blue), 
P11 (red), and P12 (green). Dharmafect was utilized as the positive control (Black). Error 
bars represent the standard deviation of triplicate experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
\ 
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Section III. Characterization of Block Ionomer Complexes Consisting of G-
Quadruplexes and aRAFT Synthesized Hydrophilic-block-Cationic Copolymers and 
Subsequent Polymeric Delivery of AS1411 
Overview 
 
Remarkable progress has been achieved in the development of anticancer 
therapeutics based on, small interfering RNA (siRNA), antisense oligonucleotides, and 
pDNA to name a few. The limiting factors for efficacious delivery of the aforementioned 
anticancer biologics are serum stability and reduced cellular internalization. A novel class 
of oligonucleotides incorporating G-rich sequences, which fold into G-quadruplexes, 
have the innate ability that appear to reduce or eliminate delivery barriers which are 
problematic to traditional oligonucleotide drugs.  Specifically, AS1411, a 26-mer which 
forms a G-quadruplex, has demonstrated in vivo success in Phase I clinical trials in 
patients exhibiting metastatic cancer; this anticancer biologic is currently in Phase II 
trials.  AS1411 inhibits cell proliferation via several possible mechanisms such as 
inhibition of shuttling, signal transduction, or modulating mRNA stability, although the 
precise mechanism has not been fully elucidated. Nonetheless, AS1411 is an aptamer for 
nucleolin, and binding to nucleolin is positively correlated to drug efficacy. To date, 
incorporation of AS1411 into polymeric vehicles has been for the purpose of cellular 
targeting.  Herein, we report the aRAFT synthesis of hydrophilic-block-cationic 
copolymers which form stable, monodisperse block ionomer complexes (BICs) with 
AS1411. These BICs were well characterized with respect to size (Rh), polydispersity 
(PDI), zeta-potential, and structure. From circular dichroism spectroscopy, no alterations 
in secondary structure were observed. The drug efficacy of AS1411 is directly correlated 
to its ability to bind to nucleolin, and AS1411’s potency was significantly reduced when 
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complexed with hydrophilic-block-cationic copolymers. These findings indicate complex 
stability plays a vital role in drug efficacy in vitro.  
 
 
Scheme 3. Synthetic outline for the preparation of poly(HPMA202-stat-APMA8) 
macroCTA (P12) and hydrophilic-block-cationic copolymers (P13–P15). 
 
 
aRAFT polymerization was employed to prepare a poly(HPMA-stat-APMA) macroCTA 
(Scheme 3). The polymerization was conducted in acetate buffer (1 M; 0.27 M acetic 
acid, 0.73 M sodium acetate) at 70 °C, utilizing 4-cyano-4-
[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CEP) and 4,4’-azobiscyanovaleric 
acid (V-501) as the CTA and initiator, respectively. The macroCTA was prepared with a 
theoretical molar feed ratio of 95:5, agreeing well with measured molar compositions 
determined via 
1
H NMR were 96 mol% HPMA and 4 mol% APMA. The macroCTA P12 
was thus determined to be poly(HPMA202-stat-APMA8). Utilizing P12 a series of chain 
extensions was performed with DMAPMA (Scheme 3). Table 5 presents the molecular 
weight, polydispersity, molar composition, conversion, and dn/dc values for the 
macroCTA (P12) and hydrophilic-block-cationic copolymers (P13–P15). From GPC (See 
Appendix) successful chain extensions are evident by shifts to lower elution volume as 
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well as the monomodal distributions. These results are in agreement with 
1
H NMR 
spectra (See Appendix). 
 P12 serves two purposes: HPMA confers water stability and APMA provides a 
functional handle to conjugate folic acid, a cellular targeting moiety. The incorporation of 
DMAPMA (P13–P15) provides cationic segments which electrostatically bind to the 
anionic phosphodiester backbone of the G-quadruplex. It is important to note that the 
preparation of BICs is formulated with a nitrogen-to-phosphate (N:P) ratio = 1 (i.e., 
neutral complexes) to ensure that off-target effects (i.e., universal transfection) and 
cytotoxicity ar minimized.  Additionally, these well-defined, monodisperse hydrophilic-
block-cationic copolymers allow for precise characterization of BICs prepared with these 
copolymers. 
Table 5 
Molecular weight (Mn, Mw) polydispersity (PDI), molar composition, conversion (ρ), and 
dn/dc values for poly(HPMA-stat-APMA) macroCTA (P1) and poly[(HPMA-stat-APMA)-
block-DMAPMA] (P2–P4) copolymers. 
Entry Mn,Th
a
 
(kDa) 
Mn,exp
b
 
(kDa) 
Mw
b
 
(kDa) 
PDI
b
 Comp
c
 
(mol%) 
ρd 
(%) 
dn/dc
e
 
P12 28.4 30.2 30.4 1.09 96:4 49 0.168 
P13 32.4 32.5 35.1 1.06 86:4:10 11 0.167 
P14 35.5 36.4 38.8 1.06 78:4:18 21 0.167 
P15 42.0 43.3 46.3 1.07 68:2:30 40 0.166 
 
aTheoretical Mn, (Mn,Th), calculated from conversion (ρ) using Mn,Th = ([M]o/[CTA]) x Mw,monomer x ρ + Mw,CTA. 
bAs determined by 
aqueous SEC-MALLS. cAs determined by 1H NMR. dConversions were determined by comparison of the UV signal at 274 nm of the 
monomer at t0 to that at tx. 
eDetermined by Wyatt Optilab DSP interferometric refractometer (λ = 690 nm). 
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Figure 34. Circular dichroism spectra of AS1411 and AS1411/hydrophilic-block-cationic 
copolymer complexes.  
 
 
Table 6 
The hydrodynamic radii (Rh), polydispersity, and zeta-potential for AS1411 and AS1411-
hydrophilic-block-cationic copolymer complexes. 
Sample Rh (nm) PDI
a
 ζ-potential (mV) 
AS1411 N/A* N/A* -11 
AS1411-P13 19 0.047 -2.16 
AS1411-P14 21 0.064 1.35 
AS1411-P15 28 0.051 2.38 
 
*The scattering intensity was too low for an accurate determination. aThe PDI was determined at 90°. 
 
G-quadruplex formation can be monitored via Uv-Vis spectroscopy (See Appendix). At 
room temperature the oligonucleotide is folded into a quadruplex, and by heating the 
sample above the melting temperature (Tm), the oligonucleotide unfolds. By subtraction 
of the absorbance scan at room temperature from the absorbance scan above theTm, a 
characteristic difference spectrum can be obtained.  This difference spectrum exhibits an 
isobestic point at 280 nm, a net hyperchromism above 285 nm, and a maximum at 295 
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nm; however, these characteristics are dependent upon oligonucleotide sequence, 
flanking sequences, and cationic counterion used. Difference spectra were recorded for 
AS1411. The spectral characteristics for AS1411 determined via Uv agree with literature 
reported characteristics, exhibiting a 295 maximum, 280 nm isobestic point, and a net 
hyperchromism. While Uv-Vis spectroscopy is a facile method for ascertaining 
quadruplex formation, this method proves difficult when utilizing BICs. Polymer 
complexation significantly increases the Tm (~40 °C), and the temperature required for 
denaturation of the quadruplex is above the boiling point of water. Nevertheless, circular 
dichroism spectroscopy (CD) can provide necessary insight into structural modifications 
of AS1411. Utilizing CD, parallel quadruplexes are characterized by the presence of a 
peak at 264 nm and a trough at 240 nm. Figure 34 presents the CD spectra for AS1411 
and AS1411/hydrophilic-block-cationic copolymer complexes. AS1411 (Figure 34, black 
curve) presents a typical CD spectrum indicative of a parallel G-Quadruplex. Upon 
complexation no noticeable shifts in the characteristic peaks are observed (See Appendix 
for λmax, λmin, and λcross-over); In contrast, we have previously demonstrated red shifting 
when hydrophilic-block-cationic copolymers are complexed with double-stranded DNA 
and RNA, B-form and A-form, respectively. Two other G-quadruplex forming sequences 
were also utilized (See Appendix), and similar results were obtained when complexed 
with hydrophilic-block-cationic copolymers. 
 
 
 
80 
 
 
 
 
Figure 35. Confocal images of AS1411 (positive control) and P15/AS1411 BICs. The 
nucleus was stained with DAPI, and the 5’-end of AS1411 was labeled with Cy3. 
  
To reduce universal transfection, BICs were prepared with a N:P = 1. Table 6 presents the 
hydrodynamic radii (Rh), polydispersity (PDI), and zeta-potential for AS1411 and 
AS1411/hydrophilic-block-cationic copolymer complexes. From zeta-potential, 
complexes prepared with P13–P15 exhibit near-neutral values. Additionally, BICs are 
monodisperse, and the Rh increases with increasing DMAPMA block length; P13 = 19 
nm, P14 = 21 nm, and P15 = 28 nm.  
Cellular entry was monitored via confocal microscopy (Figure 35). Since AS1411 
enters the cells naturally, typically by macropinocytosis, it was used as the positive 
control; AS1411 was labeled with CY3, and the nucleus was stained with DAPI. From 
Figure 35-middle row, AS1411, alone, successfully enters KB cells. Utilizing P15 as the 
drug carrier, cellular delivery is also achieved. Notably, signals from the CY3 
fluorophore are present in both the cytoplasm and nucleus; similar results are also 
witnessed when utilizing P13 and P14 (data not shown). 
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Figure 36. Cytotoxicity of AS1411 and BICs of AS1411 and P12, P14, and P15 after 48 
h and 72 h. Error bars represent the standard deviation of triplicate experiments. 
 
Having achieved cellular delivery and entry, the anti-proliferative capability was 
assessed via cell viability assays (Figure 36). The concentration of AS1411 was 
maintained at 5 μM. After 48 h (Figure 36), negligible activity occurs, achieving a ~ 15% 
reduction in cell density. After 72 h, a ~65% reduction is observed. Interestingly, 
polymeric delivery of AS1411 using P13, P14, and P15 achieve dissimilar results. After 
48 h, P13, P14, and P15 display negligible anti-proliferative activity. Additionally, after 
72 h, between 20–25% in cellular reduction is observed when using P13, P14, and P15. 
We have previously reported time-delays in maximizing gene suppression utilizing 
siRNA. It is likely that the potency of AS1411 is reduced when delivered with 
hydrophilic-block-cationic copolymers due to the increased stability provided when the 
G-quad is complexed (i.e., decomplexation requires ion exchange/substitution reactions), 
thus delivery of this anticancer biologic would necessitate an increased amount of time 
before modest drug activity can be observed, since the activity of AS1411 is presumed to 
not be catalytic.   
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CHAPTER V 
 
CONCLUSIONS 
 
Section I. Endolytic, pH-Responsive HPMA-b-(L-Glu) Copolymers Synthesized via 
Sequential Aqueous RAFT and Ring Opening Polymerizations 
 HPMA-block-(L-Glu) copolymers with controlled structures, narrow PDIs, and 
target molecular weights were prepared by sequential aqueous RAFT and ring opening 
(NCA) polymerizations followed by post-reaction hydrolysis. The block copolymers with 
tailored L-glutamic acid sequences allow formation of membrane-disruptive helical 
segments at biorelevant pH values. Red blood cell hemolysis and fPOPC release studies 
were performed, and at moderate concentrations and sufficient block lengths (α-helical 
content), pH-dependent hemoglobin and fluorescein release occurred. It is anticipated that 
the facile synthetic approach reported here will allow further development of modular 
drug/gene carriers for the efficient endosomal release of anticancer drugs. While we have 
shown membrane disruption with these novel HPMA-block-(L-Glu) copolymers, future 
studies will be necessary to evaluate efficiency and mechanistic pathways of drug/gene 
delivery in vitro.  
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Section II. Block ionomer complexes consisting of siRNA and aqueous RAFT 
synthesized hydrophilic-block-cationic copolymers: Monitoring complex dissociation  
and the effects on gene suppression 
 Aqueous RAFT was utilized to prepare poly[(HPMA-stat-APMA)-block-
DMAPMA copolymers with controlled lengths of DMAPMA. Well-defined BICs were 
prepared with siRNA and its dsDNA analogue, and the complexes formed with siRNA 
and GLuc DNA were comparable. AUC demonstrated increased binding constants with 
increasing cationic (DMAPMA) block length. Solution differential scanning calorimetry 
was conducted to determine BIC stability. The melting temperature of GLuc DNA, the 
siRNA analogue, significantly shifted to higher temperatures when complexed with 
hydrophilic-block-cationic copolymers. Furthermore, increasing DMAPMA block length 
increased the Tm of each block ionomer complex (P12 > P11 > P10). Since thermal 
denaturation of the DNA provided a large endotherm, single-stranded DNA was 
complexed with hydrophilic-block-cationic copolymers to determine thermodynamics of 
dissociation. Since no complex dissociation was observed under our experimental 
conditions, we believe that the binding constants are so high that any species dissociation 
would be below the instruments detection capability. While the precise nature of BIC 
complexation/decomplexation is not fully understood, these studies clearly demonstrate 
an increase in gene suppression with increasing DMAPMA block length, and more 
importantly, longer DMAPMA block lengths produced a time-delay in achieving a gene 
knockdown maximum. Additionally, the kinetics for achieving these maxima are 
consistent with ion exchange/substitution rates for IPECs and BICs.  While we have 
demonstrated the effect of block length on gene suppression, the effect of the cationic-
anionic registry (i.e., arrangement of cationic charges along the phosphate-helix 
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backbone) on binding strength, and subsequently, gene suppression is still under 
investigation. 
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Section III. Characterization of Block Ionomer Complexes Consisting of G-
Quadruplexes and aRAFT Synthesized Hydrophilic-block-Cationic  
Copolymers and Subsequent Polymeric Delivery of AS1411 
aRAFT was utilized to prepare poly[(HPMA-stat-APMA)-block-DMAPMA] 
copolymers with increasing DMAPMA block length (P13–P15). The HPMA segments 
confer water stability, while APMA provides a conjugation site for folic acid, a cellular 
targeting moiety. The cationic tertiary amines of DMAPMA serve to bind to AS1411, a 
G-quadruplex biologic, to form BICs. These complexes were well characterized; the 
hydrodynamic radii (Rh) increases with increasing DMAPMA block length (P15 > P14 > 
P13) and the complexes displayed near neutral zeta-potential values. Additionally, these 
complexes maintained narrow polydispersities (PDIs < 0.1). Circular dichroism 
spectroscopy (CD) was employed to ascertain structural alterations upon hydrophilic-
block-cationic copolymer binding to AS1411. Polymer binding produces no observable 
shifts in the CD spectra, indicating structural modifications do not occur when AS1411 is 
complexed. The anti-proliferative capability of AS1411 was assessed by monitoring KB 
cell viability. KB cell proliferation was observed after 48 h, but ~ 65 % reduction in 
proliferation was achieved after 72 h when utilizing AS1411. BICs were less effective, 
achieving 20–25 % reduction in proliferation after 72 h. We hypothesized that complex 
stability for these BIC systems warrants a much longer time required for complex 
dissociation (e.g., ion exchange/substitution) to occur. Further studies are ongoing to 
probe the relationships between complex stability and AS1411’s in vitro potency. 
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CHAPTER VI 
 
FUTURE RECOMMENDATIONS 
 
 The work presented in this dissertation has provided novel insights into 
overcoming polymeric drug/gene delivery barriers. We have demonstrated that siRNA 
release is dictated via an ion exchange/substitution pathway, and exploiting this pathway, 
the time to achieve a gene suppression maximum has the potential to be tailored. We have 
only demonstrated this phenomenon utilizing polymeric carriers equipped with 
protonated tertiary amines. To explore further into these structure-property relationships, 
it is recommended that two systematic studies be conducted to elucidate effects imposed 
by the cationic structure: One study to vary the amine (cation) type, and the second study 
to vary the cationic charge density.  
 Scheme 4 presents a proposed synthetic pathway to study structure-property 
relationships relative to amine type. This synthetic strategy builds upon the McCormick 
group expertise in preparing functional, modular (co)polymers. Flores et al. demonstrated 
successful RAFT polymerization of unprotected isocyanates; however, these polymers 
could not be purified, and they required immediate functionalization. In this synthetic 
strategy, the isocyante is protected with an imidazole group, which can be easily 
displaced (i.e., quantitatively) with nucleophiles. More importantly, this pathway allows 
for the total block length to be equal, thus studying each amine type will relate to the 
ionic strength of the amine. Since the cationic block remains the same, only the binding 
strength between each type of amine will differ, and therefore, increased ionic strength 
would, hypothetically, increase the time required for complete dissociation and 
subsequently, gene suppression; refer to Section II of Chapter IV. 
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Scheme 4 Proposed synthetic pathway to synthesize block copolymers with differing 
amines (1°–4°). 
 
 In the second study, charge density is the focus. Scheme 5 presents a synthetic 
method that allows for production of polymeric carriers that vary in charge density. It is 
anticipated that a charge density exists such that dissociation may be monitored directly. 
To begin, the macroCTA remains similar to previous reports, and charge separation is 
achieved via increasing the molar composition of HPMA during chain extensions with a 
cationic monomer; see Table 7 for proposed molar compositions. 
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Scheme 5. Proposed synthetic pathway for the preparation of poly[(HPMA-stat-APMA)-
block-(HPMA-stat-DMAPMA)] copolymers. In this method, The HPMA molar content 
in the chain extension will be varied to ensure charge separation (i.e., reduced charge 
density). 
 
 
 Table 7 
Proposed hydrophilic-block-cationic copolymer compositions and degree of 
polymerization. 
HPMA-stat-Folate Block 
(w:x) 
HPMA-stat-Cationic Block  
(y:z) 
Total Cationic 
Repeats (DP) 
95:5 
0:100, 10:90, 20:80, 30:70, 40:60, 
50:50, 60:40, 70:30, 80:20, 90:10, 
100:0 
Maintained at 
25 
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The final study aims to determine enzymatic interactions with BICs and enzymes. This 
study has two purposes. The first purpose is to elucidate kinetics of BIC ion 
exchange/substitution, and the second purpose is to ascertain the inhibition mechanisms 
(i.e., are hydrophilic-block-cationic copolymers competitive or noncompetitive inhibitors 
and are they reversible). 
 Consider the following scenario presented in Scheme 6. This scheme describes the 
formation of hydrophilic-block-cationic (HbC)-siRNA BICs which will undergo an 
irreversible exchange reaction with an analogous dsDNA. This exchange reaction is 
irreversible since an RNase will be present to selective cleave the siRNA into 
mononucleotides. It should be noted that human RNases are not capable of 
mononucleotide cleavage, and the RNase used should be purchased from EpiBio 
(Ribboshredder™-RS12100). 
 
 
 
Scheme 6. Proposed reaction method for the determination of BIC ion 
exchange/substitution kinetics, and the inhibition mechanism. 
 
 
 Utilizing a photodiodearray spectrophotometer equipped with a stop-flow cuvette, 
the kinetics of BIC ion exchange/substitution as well as the inhibitory mechanisms may 
be elucidated. One will directly observe the formation of siRNA mononucleotides via an 
increase in absorbance at 260 nm. From this absorption increase kb may be determined. 
90 
 
 
The challenge in this design arises from the fact that nucleases obey Michaelis-Menten 
kinetics, represented as kMMK in the above scheme.  A brief overview of enzyme kinetics 
is supplied, but any introductory biochemistry text will present the derivation of 
Michaelis-Menten equation in detail.  An enzyme E combines with substrate S to form an 
ES complex, with a rate constant k1. ES can dissociate to E and S, with a rate constant of 
k-1, or ES can proceed to form product P, with a rate constant of k2 (See Equation 3). 
      (eq 3) 
The ES complex can also be reformed from E and P by the reverse reaction with a rate 
constant k-2. However, one may simplify these reactions by considering the rate of 
reaction at times close to zero when there is negligible product formation, thus no reverse 
reaction (i.e., k-2[P] ≈ 0) (See Equation 4): 
   (eq 4) 
The rate of reaction at times close to zero is determined by V0, and it is determined for 
each substrate concentration by measuring the rate of product formation (siRNA 
mononucleotides) at early times, typically within the beginning 5 % of the reaction. V0 
can be related to the rate of catalysis to the concentrations of substrate and enzyme and 
the rate of the individual steps via the steady-state approximation to give Equation 5 
    (eq 5). 
Equation 8 is simplified by defining a new constant, KM, called the Michaelis constant: 
    (eq 6). 
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After rearranging and solving for [ES], the equation becomes 
    (eq 7). 
Since the substrate concentration is usually present at a much higher concentration than 
the enzyme, the concentration of uncombined substrate [S] is very nearly equal to the 
total substrate concentration. Furthermore, the concentration of uncombined enzyme [E] 
is equal to the total enzyme concentration minus the concentration of the ES complex. 
Using this information,V0 may be determined utilizing Equation 8: 
   (eq 8) 
in which Vmax = k2[E]T, and [E]T is the total enzyme concentration. Equation 10 is known 
as the Michaelis-Menten equation. 
 
 
Figure 37 Enzyme kinetic plots representing typical Michaelis-Menten kinetics (A) and a 
Lineweaver-Burk plot (B). 
 
 
 This equation is important for two reasons, the equation describes the first order 
reaction rate (i.e., at early times [S] << KM, V0 = (Vmax/KM)[S])) as well as the zero order 
reaction rate when [S] >> KM (V0 = Vmax) (See Figure 37-A). Since one may determine 
Vmax, and the total enzyme concentration is known, then the rate of catalysis k2 may be 
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determined, and in our case, k2 = KMMK (See Scheme 6). It should be noted that there are 
two methods for the determination of Michaelis-Menten parameters. The first method 
utilizes a double reciprocal plot — the Lineweaver-Burk plot (See Equation 9 and Figure 
37-B). 
   (eq 9) 
This plot yields a straight line with a y-intercept of 1/Vmax and a slope of KM/Vmax. The x-
intercept is -1/KM. This method is not recommended as a means to determine the 
Michaelis-Menten parameters because it overestimates the x-intercept and overestimates 
the slope. In the second method, a double-floating parameter fit is applied to the 
Michaelis-Menten kinetic data. This procedure is easily accomplished utilizing Origin or 
GraphPad Prism graphing software, and in the case of enzyme kinetics, the equations and 
fitting function are built-in. This method is the most accurate means to determine the 
Michaelis-Menten parameters. 
 
Figure 38. Data representative of competitive inhibition. 
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 The determination of k2 allows for the determination kb which is the rate of BIC 
ion exchange/substitution. Once the rate of BIC exchange/substitution is known, the 
inhibitory mechanism may be ascertained. This section will provide a means to determine 
reversible inhibitors. 
  There are three types of reversible inhibitors (See Scheme 7), competitive, 
uncompetitive, and noncompetitive. In competitive inhibition (See Figure 38), the 
inhibitor competes with the substrate for the active site. The dissociation constant for the 
inhibitor (Ki) is given by Equation 10 
   (eq 10) 
in which [E] is the enzyme concentration, [I] is the inhibitor, and in our case, the 
hydrophilic-block-cationic copolymer utilized, and [EI] is the concentration of enzyme-
inhibitor complex. The smaller the Ki, the more potent inhibition. The effect of a 
competitive inhibitor is to increase the apparent value of KM. This new value of KM, 
called KM, APP, is determined via Equation 11. 
   (eq 11) 
 In uncompetitive inhibition (See Figure 39), the inhibitor binds only to the ES 
complex.  This enzyme-substrate-inhibitor complex ESI (i.e., BICs interacting with 
enzyme) does not go on to form any product thus lowering Vmax. For uncompetitive 
inhibition, a lower concentration of S is required to form half the maximal concentration 
of ES, and the apparent value of KM is reduced. 
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Scheme 7. Reaction pathways for competitive, noncompetitive, and uncompetitive 
inhibition. 
 
 In noncompetitive inhibition (See Figure 40), substrate can bind to the enzyme-
inhibitor complex; however, the enzyme-inhibitor-substrate complex does not proceed to 
form product. The value of Vmax is decrease to a new value, Vmax,app, and the value of KM 
is unchanged. Vmax,app can be determined from Equation 12. 
 
 
Figure 39. Data representative of uncompetitive inhibition. 
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        (eq 12) 
 Noncompetitive inhibition results in solutions that behave similarly to a dilute 
concentration of functional enzyme, thus the lowering of Vmax  is observed while KM is 
unaltered. 
 The most facile method to ascertain the inhibitory mechanism is via double-
reciprocal plots (See Figure 41). In competitive inhibition, the y-intercept remains 
unchanged; however, the slope is increased. In the presence of a competitive inhibitor, 
Equation 8 is replaced by Equation 13 (See Figure 41-B). 
   (eq 13) 
 In uncompetitive inhibition, the inhibitor combines only with the enzyme-
substrate complex. Therefore, Equation 10 is replaced with Equation 16 (See Figure 41-
C). 
   (eq 14) 
 
 
Figure 40. Data representative of noncompetitive inhibition. 
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In noncompetitive inhibition, the value of Vmax is decreased to the new value Vmax,app, and 
the y- intercept is increased. The new slope, which is equal to KM/Vmax,app, is increased by 
the same factor (See Figure 41-D). 
 From these plots, the inhibitory mechanism may be ascertained. 
 
 
Figure 41. Representative double-reciprocal plots for Lineweaver-Burk (A), competitive 
inhibition (B), uncompetitive inhibition (C), and noncompetitive inhibition (D). 
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APPENDIX A 
 
SUPPLEMENTARY TO SECTION I OF CHAPTER IV 
 
 
Figure A1  Absorbance of ninhydrin at 570 nm versus amine concentration for D-alanine 
(filled circles) and P2 (open, blue square). 
 
Figure A2. Fluorescence intensity of fPOPC at pH 7.4. fPOPC was incubated with P1 and 
P6–P8 copolymers. Triton-X100 was utilized as the positive control. No observable 
increase in fluorescein release was determined at pH 7.4 when incubated with P6–P8 
copolymers. 
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Figure A3. Percent hemolysis release as a function of concentration for P1 and P6–P8 
copolymers. Triton-X100 was utilized as the positive control. 
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APPENDIX B 
 
SUPPLEMENTARY TO SECTION II OF CHAPTER IV 
 
 
Figure B1.
 1
H NMR of P9, P10, P11, and P12 (the macroCTA and subsequent chain 
extensions with DMAPMA). 
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Figure B2. Circular dichroism melting spectra of GLuc DNA. 
 
 
 
Figure B3. Circular dichroism melting spectra for siRNA. 
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Figure B4. Heating and cooling solution DSC thermograms for (A) GLuc DNA, (B) 
hydrophilic-block-cationic copolymers (P10–P12), and (C) DNA-hydrophilic-block-
cationic copolymer complexes. No hysteresis is evident between heating and cooling (i.e., 
these systems are reversible). 
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Figure B5. Solution DSC thermograms illustrating the scan rate dependence for (A) 
GLuc DNA, (B) DNA-P10 complexes, (C) DNA-P11 complexes, and (D) DNA-P12 
complexes. The melting temperature (Tm) remains constant with respect to scan rate (i.e., 
these systems are in equilibrium). 
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Figure B6. Cell viability assays of P10, P11, and P12. 
 
Table B1  
The melting temperature (Tm) calorimetric enthalpy (ΔHCal), van’t Hoff enthalpy (ΔHVH), 
entropy (ΔS) Gibb’s free energy (ΔG) for GLuc DNA and GLuc DNA-hydrophilic-block-
cationic copolymer complexes. 
Sample 
ΔHCal 
(kcal/mol) 
ΔHVH 
(kcal/mol) 
ΔS 
 (kcal/mol *K) 
ΔG 
(kcal/mol) 
Tm (°C) 
Gluc DNA 240 240 106 204 54.4 
DNA-P10 420 367 120 340 88.8 
DNA-P11 483 686 140 413 90.2 
DNA-P12 461 1900 143 393 91.8 
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APPENDIX C 
 
SUPPLEMENTARY TO SECTION III OF CHAPTER IV 
 
 
Figure C1. Light scattering traces of poly(HPMA202-stat-APMA8) macroCTA (P1), and 
subsequent chain extensions with DMAPMA (P2–P4). 
 
 
105 
 
 
 
Figure C2. 
1
H NMR of poly(HPMA202-stat-APMA8) macroCTA (P1) and subsequent 
chain extensions with DMAPMA (P2–P4). 
 
Figure C3. Uv/Vis spectroscopy of conjugated folic acid to P2, P3, and P4. 
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Figure C4.Heated (Red), cooled (Black), and difference (Blue, dashed) Uv/vis spectra of 
(A) 15APT, (B) 27S, and (C) AS1411 G-quadruplexes. 
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Figure C5. Circular dichroism spectra of 27S and hydrophilic-block-cationic 
copolymer/27S BICs. 
 
Table C1  
The maximum, minimum, and cross-over for AS1411 and hydrophilic-block-cationic 
copolymer/AS1411 BICs. 
Sample λMax (nm) λMin (nm) λCross-over (nm) 
AS1411 261 238 252 
P2-AS1411 261 239 255 
P3-AS1411 261 238 253 
P4-AS1411 261 239 255 
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Table C2  
The maximum, minimum, and cross-over for 27S and hydrophilic-block-cationic 
copolymer/27S BICs. 
Sample λMax (nm) λMin (nm) λCross-over (nm) 
27S 264 241 251 
P2-27S 264 241 250 
P3-27S 264 241 252 
P4-27S 264 241 255 
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